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ABSTRACT 
 
Samantha Puvanesarajah; Associations between mode of detection, imaging features, and breast 
cancer subtype in the Carolina Breast Cancer Study 
(Under the direction of Melissa A. Troester) 
Purpose: Symptomatic cancers generally have poor prognosis compared to screen-detected 
cancers and likelihood of screen detection may vary as a function of biological subtype or 
imaging characteristics of the breast cancer. The aims of this study were to study the association 
between breast cancer subtype and 1) mode of detection and 2) radiologic/ imaging features. 
Methods: In the first aim, we identified 1497 women diagnosed with primary invasive breast 
cancer from a linked data set between the Carolina Breast Cancer Study and the Carolina 
Mammography Registry. Among recently-screened (within 24 months) women (n=370, 25%), 
45% of cancers were screen-detected (N=165), and 55% were interval-detected (N=205). 
Interval cancer was evaluated in association with clinical and genomic characteristics. In the 
second aim, 412 women with mammograms within 2 years before to 30 days after diagnosis 
were identified and associations between subtype and radiologic features were assessed. 
 Results: Interval cancer was associated with large tumors (>2 cm) (OR=2.3; 95% C.I.: 1.5, 3.7), 
positive nodal status (OR=1.8; 95% C.I.: 1.1, 2.8), and triple negative cancer (OR=2.5; 95% C.I.: 
1.1, 5.5).  Associations between interval detection and genomic characteristics were strong, and 
suggested that the vast majority of screen-detected cancers were indolent (96% were low risk of 
recurrence; 71% were Luminal A). Both young (<50) and African-American women showed 
higher relative frequency of masses and lower frequency of calcifications compared to older (≥ 
50) and White women. Masses were less frequent among interval-detected vs. screen-detected 
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women (33% vs. 46%, p=0.04). Relative to Luminal A breast cancers (42% presenting as 
masses), PAM50 Basal-like and HER2-enriched subtypes were more likely to present as masses 
(59% and 72%, respectively). Few Basal-like and ROR-PT high cancers presented with 
calcifications (n=4/49 Basal-like and n=3/30 ROR-PT high). 
Conclusions: Underlying cancer biology plays a role in screen detection; some interval cancers 
arise from aggressive tumor biology and distinct molecular and genomic subtypes of breast 
cancer present with distinct mammographic features. Results of this research add to our 
understanding of mammographic screening limitations and helps prioritize research questions in 
the context of evolving radiologic practices. 
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CHAPTER 1: BACKGROUND 
1.1 Breast cancer epidemiology 
Breast cancer is the second leading cause of cancer death among US women1. Though breast 
cancer survival has improved over the last two decades2, breast cancer remains an important 
public health issue in the US. It is estimated that approximately 12% of women in the US will be 
diagnosed with breast cancer during their lifetime3. In 2013 alone, there were an estimated 
232,340 new cases of breast cancer4 and 39,260 breast cancer deaths5. Breast cancer mortality 
has declined over the past 25 years, by approximately 2% a year6; however, racial and ethnic 
disparities have increased due to a greater decline in mortality among white women compared to 
minority women6.  Previous studies have suggested that mortality differences may be partially 
attributed to lower adherence to screening and more aggressive tumors at diagnosis, but tumors 
are also more aggressive in black women after conditioning upon screening initiation7.  Better 
understanding of differences in prevalence of aggressive breast cancer subtypes requires 
resolution of how mammography use and mammographic detection contribute to tumor 
aggressiveness patterns overall, and also in black and white women. 
1.2 Mammography 
Mammography is the most common breast cancer screening method, and consists of a low 
dose x-ray image of the breast, which can be either recorded on film or digitally. In a 
mammographic image, adipose content, which is radiologically lucent, will appear dark while 
fibroglandular content, which is radiologically dense, will appear light. Tumors, which are 
radiologically dense, will also appear light on mammograms. In a national sample of US women, 
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the proportion of women over 40 who had a mammogram within the last two years increased 
from 29% in 1987 to 72.4% in 2003, and has remained fairly stable in both Whites and African 
Americans8. Newer screening techniques, such as tomosynthesis and ultrasound, are starting to 
become more utilized in the US, but are still far from reaching the widespread use of 
mammography. 
1.2.1 Risks and benefits 
 The purpose of screening is to advance the time of diagnosis to an earlier more treatable 
cancer stage thereby reducing mortality9,10. Mammography has been shown to reduce breast 
cancer mortality in both randomized control trials11,12 and population-based screening 
programs13,14. However, though it has been shown that breast cancer screening increases the 
proportion of early stage cancer, a lower decrease in incidence of advanced stage cancer has been 
observed, suggesting overdiagnosis of indolent cancers15-17. This has led to some of the 
controversy surrounding mammography with little agreement on screening strategies, risks and 
benefits, and the ideal target population, and with some questioning its true efficacy for 
screening18. A recent meta-analysis found that while mammography reduced breast cancer 
mortality, the magnitudes of effect were small (8 deaths prevented per 10000 women over 10 
years for those aged 50-59)19. This, in addition to risk of false positive results20 and their 
associated negative psychological effects, has led to the considerable debate around 
mammography use in asymptomatic women.  
 Disagreements are especially prevalent concerning women 40-49, a group for which the 
harms may outweigh the benefits, contributing to different screening guidelines among national 
organizations21.  As summarized by the USPSTF, although slightly more cancers are detected 
when starting screening at age 40 vs. age 50, the number of unnecessary breast biopsies and 
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overdiagnosed breast tumors are also increased22. However, a meta-analysis of randomized trials 
shows a 15% reduction in mortality among women who were invited to begin screening from 40-
4923. When coupled with the finding that screening mammography sensitivity is lower in 
younger women24, it is understandable why there is a great deal of variability in screening 
recommendations for women in this younger age group. Disagreement also exists around 
screening regimens for women over the age of 75 as reviewed by Freedman et al.25. It appears 
that dissimilarity in recommendations arises because the risks and benefits of mammography 
differ for this older population compared to women < 75; even though older women have a 
higher probability of developing breast cancer26, they may not experience as much of a survival 
benefit through early detection as younger women19.  
1.2.2 Mammography guidelines 
 Mammography guidelines during CBCS recruitment periods are shown in Appendix A. 
Until 1997, mammography recommendations were fairly consistent between national 
organizations such as the American Cancer Society (ACS) and the American Congress of 
Obstetricians and Gynecologists (ACOG) each calling for mammography every 1-2 years for 
women 40-49 and annual mammography for women 50 and older27,28. However, both the ACS  
and the United States Preventive Services Task Force (USPSTF) decreased age of initiation of 
annual mammography to 40 years in 1997 and 2002, respectively28,29. This is in contrast to the 
ACOG, who remained with their previous guidelines30. In 2009 further discordance developed 
when USPSTF updated their guidelines, increasing the age of initiation to 50 and recommending 
only biennial screens31. While it is difficult to determine how each of these strategies have 
individually affected breast cancer mortality rates in the US, models suggest that annual 
screening beginning at age 40 confers a greater reduction in breast cancer mortality (37.8 deaths 
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per 1000 women) relative to biennial screening after age 50 (25.8 deaths per 1000 women)32. 
Current screening recommendations in 2016 are still different from those in 2010. The USPSTF 
continues to recommend biennial screening after age 5033, while the American Cancer Society 
suggests annual mammograms between ages 45-54, and biennial mammograms for women 55 
and older, with screening continuing while a women has a life expectancy of 10 years or 
longer34.  
 The lack of consensus in guidelines may have affected mammography screening rates; 
several studies have evaluated changes in screening behavior after the guidelines were 
announced. Three years after the 2009 USPSTF recommendations, using population-based data 
from the Behavioral Risk Factor Surveillance System (BRFSS), there was no significant change 
in age of screening initiation35, while another study found decreased screening mammography 
after the guidelines were announced36,37. Still other studies based on self-reported data found no 
change38 or increased screening since 200939,40. Surveys administered to physicians 2-3 years 
after the 2009 USPSTF guideline change showed that the majority were not adhering to the new 
guidelines41,42, which could lead to patients receiving conflicting recommendations. Confusion 
by health providers and among women43,44, could have long-term effects on mammography 
initiation and adherence that remain to be seen, especially given that provider recommendation is 
a very strong predictor of mammography utilization45,46. 
1.3 Mode of detection 
1.3.1 Definitions 
Breast cancers can be categorized into three general groups based on mammographic 
mode of detection: screen-detected cancers (SDC), which are cancers that are detected by a 
screening mammogram; interval cancers (IC), which are cancers that are detected after a 
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negative mammogram in the interval between regular screenings; and clinically detected cancers 
(CDC), which we define as cancers that are neither screen nor interval-detected. The rate of 
interval cancers has been reported as being from 14% to 39%47-54 (Appendix B, Table B1), and 
vary depending on screening interval.   
1.3.2 Predictors of mode of detection 
The factors that lead to missed mammographic detection of cancer are complex and 
encompass individual factors such as demographics and cancer characteristics, community 
factors such as screening facility availability and quality, and higher level characteristics such as 
national screening recommendations. All of these factors are often interrelated. One example of 
this is screening interval, which is the time between cancer screenings. Screening interval has 
been shown to be associated with mode of detection, with higher interval cancer rates measured 
with increasing screening interval55-57. Screening intervals can be determined using screening 
recommendations from national organizations. Facility distance can also determine screening 
interval; women who live a great distance from a facility may choose to screen less often 
compared to a woman who lives relatively near to a facility. In addition, women who have had a 
previous diagnosis of breast cancer and have chosen not to have a full mastectomy or women 
who have a strong family history of breast cancer may have shorter screening intervals.  
For this project, we will be focusing on patient and tumor characteristics and how they 
are associated with mode of detection. Of the patient characteristics, age, race, mammographic 
density, and family history are predictors of interest in this study.  
Mammographic density 
One of the strongest risk factors for breast cancer is mammographic density58-60. 
Mammographic density is a measure of the epithelium and stroma, or fibroglandular, content of 
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the breast and can be determined using mammography. Women who have a higher relative 
proportion of fibroglandular content in their breast will have a higher mammographic density 
compared to women who have breasts that are predominantly fat tissue. Since mammographic 
density became used as a method to classify breasts, several different classifications methods 
have been used. The most commonly used classification for assessing mammographic density in 
the United States is the breast imaging and reporting data system (BI-RADS), developed by the 
American College of Radiology. BI-RADS is a semi-quantitative assessment, and is categorized 
from a (breasts are almost entirely fatty) to d (breasts are extremely dense. 
Mammographic density is effected by several factors. Mammographic density is known 
to decrease with age and BMI61. In addition, hormone therapy is associated with increased 
density62.  Several studies have described the relationship between mammographic density and 
mode of detection. Compared to screen-detected cancers, cancers that are non-screen-detected 
are more likely to occur in more dense breasts63-65. This relationship may be due in part to 
masking bias. Masking bias can occur in mammographic screening because both fibroglandular 
content and tumors have the same appearance on mammograms; this may cause some tumors to 
be missed in women in dense breasts. HRT use has been shown to be associated with interval 
cancers in several studies66-70; it is unknown if this relationship is due to the effect of HRT on 
mammographic density, though it is likely since a study within the BCSC found that HRT use 
was not an independent predictor of mammographic accuracy, but effects accuracy through its 
effect on breast density71. 
To assess the association between mammographic density and mode of detection in the 
absence of masking, studies have performed analyses stratified by density. Interval breast 
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cancers that arise in fatty breasts are more aggressive than interval cancers found in dense 
breasts72-74. 
Age 
Younger age (age <50) has been reported to be associated with non-screen-detected 
cancers, including interval cancer48-50,68,75-77. The sensitivity of screening mammography 
increases with age24, with one study showing an increase from 69.5% among women 30-39 to 
87.7% in women 60-6978. Among women 50-69, the relationship between age and mode of 
detection may be confounded by hormone replacement therapy (HRT) use; after accounting for 
HRT use, age was not related to mode of detection among 60,000 women in the National Health 
Service Breast Screening Program79 and 122,000 women in the Million Women Study80, both 
aged 50-65.  
Race 
Racial disparities in breast cancer mortality could result from several factors, including 
mammography use, quality of mammography received, and breast cancer biology. Racial 
differences in mammography use have been well studied, and the racial disparity in 
mammography screening between Black and White women has diminished over the past two 
decades, with both races reporting similar mammography use over the last few years26. Although 
mammography usage is similar, there has been some research suggesting that Black women are 
more likely to receive screenings from facilities with less favorable characteristics such as 
lacking access to academic facilities, breast imaging specialists, and digital mammography81. 
The rates of interval cancer by race are less well studied. In a population of Chicago 
women, based on self-report, Black women were more likely to have an interval cancer 
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compared to White women; the authors concluded that the racial disparity was mostly accounted 
for by tumor and facility characteristics82. 
In a study conducted within the Breast Cancer Surveillance Consortium, African-
American women were both more likely to have received inadequate screening and to present 
with larger and higher grade tumors than white women7. Among those that are screened, both 
digital and film-screen mammography perform equally well among white and black women83,84, 
suggesting that mortality differences seen between the races beyond screening patterns may be 
due to tumor biology. 
Family history/ BRCA status 
The relationship between family history and mode of detection is inconclusive47,63,70,74. 
As mentioned previously, women with known BRCA mutations or have relatives with known 
BRCA mutations are often recommended to start screening earlier and to screen more often than 
woman with average risk, which is important to keep in mind when considering associations 
between BRCA status and mode of detection. Possessing a mutation in the BRCA gene is a 
strong predictor of developing breast cancer, with penetrance up to 88%85,86. Women with 
BRCA1 mutations are more likely to have triple negative cancer compared to women with no 
mutation87. There are also some differences in tumor biology and mode of detection with respect 
to which BRCA gene is mutated, which might explain why there are conflicting results for the 
association between family history and mode of detection, since most studies group BRCA1 and 
BRCA2 mutations together. Women with BRCA1 mutations are more likely to present with 
triple negative cancers and have lower mammographic detection rates, whereas women with 
BRCA2 mutations are more likely to have hormone receptor positive tumors and higher 
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mammographic detection rates88. In addition BRCA1 carriers were more likely to present with 
interval cancers compared to BRCA2 carriers88,89. 
1.3.3 Tumor characteristics by mode of detection 
Compared to screen-detected cancers, clinically-detected and interval cancers generally 
have poorer survival90-93 and more negative prognostic factors, including larger size, lymph node 
involvement, higher stage, higher grade,  and are ER- and PR- 48,67,90,91,93-95. In addition, lobular 
histology is more common among interval cancer compared to screen-detected cancers48,53. 
While differences between screen-detected and non-screen-detected cancers are marked, the 
differences between interval and clinically-detected cancer are mixed, with some studies 
reporting that they have similar clinical factors and survival 67,96-101, and others reporting that 
women with interval cancers have prognostic factors, such as grade and tumor size that fall 
between those of women with screen-detected and clinically-detected cancer102,103. Studies of 
interest are summarized in Table B2 (Appendix B).  
1.4 Breast cancer subtype 
Breast cancer is a heterogeneous disease. Characterizing heterogeneity has historically 
emphasized differences according to hormone receptor status, namely estrogen receptor (ER) and 
progesterone receptor (PR). However, there is additional heterogeneity within receptor-defined 
classes, necessitating a more fine-tuned approach when classifying breast cancers. As first 
reported by Perou in 2000104, there are several subtypes of breast cancer based on RNA 
expression patterns, which have been confirmed in several populations105,106. These subtypes are 
luminal, HER2+/ enriched, basal, and normal-like. The luminal subtypes of breast cancer are ER 
positive and express genes that are similar to luminal mammary epithelial cells, while basal-like 
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tumors are ER negative and express genes associated with the myoepithelial cells of the outer 
layer of the breast duct105,107.  
In general, basal-like tumors have worse prognostic factors compared to luminal tumors; 
basal-like tumors are more likely to be invasive ductal cancers, high grade, and have a high 
proliferative index108-110. The basal-like subtype of breast cancer has been shown to have poor 
prognosis compared to the other intrinsic subtypes92,111-113, and is more common among young 
and African-American women111,114-116. Subtype can be distinguished using 
immunohistochemical, RNA, or protein-based methods as described below. 
1.4.1 IHC-based subtypes and mode of detection 
Immunohistochemical (IHC) methods have been developed for subtype classification, 
and utilize formalin-fixed paraffin embedded tissues117. In studies using intrinsic subtyping, 
Luminal A tumors are generally those that are ER+/PR+/HER2- or ER+/PR-/HER2-. Luminal B 
tumors differ from Luminal A tumors in that they are positive for HER2; these tumors are 
ER+/PR+/HER2+ or ER+/PR-/HER2+. Basal-like tumors are triple negative (ER-/PR-/HER2-), 
and express either EGFR or CK5/6. IHC is the most commonly used classification scheme for 
molecular subtypes of breast cancer in epidemiologic studies. 
Studies of interest examining associations between mode of detection and molecular 
subtype are summarized in Table B3 (Appendix B). Very few studies examining mode of 
detection have used basal-like breast cancer in their analyses118,119, with the majority of studies 
using the triple-negative breast cancer phenotype68,76,77,92,113,120. Though triple-negative and 
basal-like breast cancers overlap, the two designations are not interchangeable121-124.  Basal-like 
and triple negative breast cancers have differing tumor characteristics; in a study that reclassified 
triple negative tumors using gene expression profiling, basal-like tumors were found to be of a 
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higher grade and have a larger tumor size compared to non-basal-like triple negative tumors121. 
This emphasizes the importance of using 5-marker IHC subtyping to differentiate these two 
subtypes in future studies. 
The studies that have examined IHC subtypes in association with mode of detection have 
tended to be small68,77,118 (<200 participants) and studies with larger populations were 
demographically very different from CBCS92,125,126. Thus there is still more to be studied with 
respect to how mode of detection relates to IHC-defined intrinsic subtypes. 
1.4.2 PAM50 subtypes and mode of detection 
While some important advances in understanding the epidemiology of breast cancer have 
resulted from the use of IHC surrogates, new methods can better resolve distinct subtypes using 
tens to hundreds of genes. PAM50 is a multi-gene classification method, and is a gold standard 
for breast cancer subtyping, using the expression of 50 genes127. Using the expression of these 
genes, breast tumors can be classified into 5 intrinsic subtypes: luminal A, luminal B, HER2-
enriched, basal-like, and normal-like. This method is more accurate in recapitulating subtypes 
based upon thousands of genes, and may be particularly useful in resolving epidemiologic 
differences between luminal A and luminal B breast cancers128. To our knowledge, only one 
study has reported associations between mode of detection and PAM50 subtypes129, and no 
studies have examined associations with other PAM50 derived variables, such as the 
proliferation signature.  
1.4.3 p53 and mode of detection 
 Wild type p53 is a tumor suppressor protein that plays a role in controlling the cell cycle 
and inducing apoptosis when a cell is damaged beyond repair130,131. Mutations in p53 are found 
in 20-30% of breast cancers132. The absence of p53 mutations is associated with longer disease 
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free and overall survival133-135.  p53 status can be captured using IHC methods, or by application 
of an RNA-based gene signature.   
Our interest in studying different molecular signatures in relation to mode of detection 
reflects the overarching hypothesis of this work: that the underlying cancer biology of screen-
detected and interval cancers may be different.  Previous lines of evidence have also supported 
this hypothesis. It has recently been hypothesized that cancers that grow large enough to be 
detected may harbor mutations that distinguish them from non-detectable cancers. In other 
words, certain mutations lead to the rapid expansion of a clonal population which contributes a 
large proportion of tumor mass, leading to detection136. Considering interval cancers, the 
majority of these cancers have increased cell proliferation49,97 , and therefore interval cancers 
may harbor a similar or shared mutations that caused accelerated growth between the previous 
negative mammogram and detection. In line with this hypothesis, studies report that cancers with 
a p53 mutation are more prevalent among interval cancers compared to screen-detected 
cancers70,138,139. Although no study has specifically examined somatic mutations of interval vs. 
screen-detected cancers, beyond p53 and BRCA, one study reported copy number imbalances 
between screen-detected and clinically detected cancers in areas of the chromosome that are 
highly related highly malignant breast cancers120, suggesting that tumor genetics may be useful 
in identifying women with indolent cancers. In the current study, we will revisit associations 
between p53 status and mode of detection using both IHC and RNA-based classification of p53 
status. 
1.5 Imaging features 
There are several mammographic imaging features that are used in the detection and 
diagnosis of breast cancer including calcifications, masses, asymmetry, and architectural 
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distortion. Masses are the most common feature associated with cancers, followed by 
calcifications, architectural distortion, and asymmetry140,141. Documentation of each of these 
characteristics is highly associated with screening use. 
1.5.1 Masses 
 Masses are a relatively common imaging feature for breast cancer; in a study using data 
from a prospectively collected hospital database, masses alone were present in 61% of detected 
breast cancers, while both masses and calcifications were present in 14% of cancers141. These 
proportions appear to change based on the population, as a series of patients from a hospital 
based in China found that masses, and masses along with calcifications, were each found in 
approximately 40% of cancers142. 
1.5.2 Calcifications 
Calcifications can present with or without visible masses. Calcifications are non-palpable 
calcium deposits that can be found in breast tissue and are used in the detection and diagnosis of 
breast cancer. They can be visualized using mammography, appearing as bright spots on 
mammograms, and can present with both benign and malignant breast lesions. Calcifications 
have been found to be present in approximately 40% of non-palpable breast cancers143 and up to 
90% of DCIS cases144. Presence of calcifications predicts poor breast cancer survival145, with 
women with casting-type calcifications having the worst prognosis146. Although the exact 
mechanism for how calcifications develop is unknown, they have been categorized into two 
categories based on composition, those made of hydroxyapatite and those made of calcium 
oxalate and it is believed that hydroxyapatite calcifications evolve more rapidly and may be the 
product of an active secretory process, while calcium oxalate calcifications are more likely to 
arise in benign lesions147.  
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1.5.3 Breast asymmetry 
Breast asymmetry occurs when asymmetrical breast density is present either within a 
breast or between two breasts. Though less common than calcifications and masses, it is still 
useful in cancer detection and shares similar positive predictive values at screening140. Cancers 
identified based on asymmetry are frequently false positives; it is posited that this may be 
because what was viewed as asymmetry may actually be the superimposition of normal breast 
structures140. However, upon a recall visit, additional views that are used to assess asymmetry 
more closely may lead to cancer detection. 
1.5.4 Architectural distortion 
Architectural distortion is a distortion of the normal breast architecture and is the third 
most common mammographic feature of non-palpable breast cancer148. Although only 
representing 6% of abnormalities detected by screening148, it has a high positive predictive value 
for cancer at both screening and diagnosis140, and both this feature and asymmetry present for 
breast cancers that were missed at screening mammography149-151. As with calcifications, 
architectural distortions can occur due to both benign (e.g., fat necrosis or radial scars) and 
malignant causes (e.g., DCIS or breast cancer). In a study that reclassified false negative 
mammograms, those that could have had a prognostic gain (been diagnosed at a lower stage) 
with early detection presented with a higher proportion of architectural distortion compared to 
cancers with no prognostic gain152. 
1.5.5 Relationship between imaging features and subtype 
There have been a small number of studies published that have examined the association 
between breast cancer subtype and imaging features. HER2+ cancers are more likely to present 
with calcifications than other subtypes of breast cancer141,153,154, while luminal and basal cancers 
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are more likely to present with masses154,155. A review by Gao et al., showed that while triple 
negative breast cancers typically presented with masses, they were less likely to also present with 
calcifications, asymmetry, and architectural distortion than ER+ or HER2+ cancers142. There 
have been no studies that examined associations between p53 or PAM50 subtype and 
mammographic features. 
1.5.6 Relationship between imaging features and mode of detection 
 The relationship between mode of detection and imaging features is mixed. In a study 
conducted within a Spanish breast cancer screening program, a similar proportion of screen-
detected and interval cancers appear to present with masses (63.3 vs. 60.5) and distortions (11.7 
vs. 11.1); however screen-detected cancers had more calcifications (12.7 vs. 4.6)155. Similar 
patterns were seen with respect to mass and architectural distortion in a study conducted within 
the British National Public Health Service Breast Screening Program, except calcifications were 
equally as likely to be present between screen and interval-detected cancers156.  
1.6 Misclassification of interval cancers 
Interval cancers can be further divided based on retrospective review into true interval 
cancers (cancers that present with normal/benign features on previous screening mammogram), 
false negatives (cancers that were detectable on previous mammogram based on retrospective 
review), minimal-sign (cancers that show detectable but non-specific features at previous 
screening), and occult tumors (cancers that show clinical signs of disease but no mammographic 
abnormalities)72. Studies that have done this retrospective review have found that about 50% of 
interval cancers are true interval cancers72,157,158. True interval cases have similar phenotype 
distributions to minimal sign cancers, whereas false negative and occult tumors were more 
similar to screen-detected cancers72.  
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1.7 Digital vs. film mammography 
Full field digital mammography (FFDM) has increasingly replaced screen film 
mammography (SFM) due to the technological advances that it provides, including images of 
higher resolution, the ability to adjust contrast, and increased efficiency of image storage. FFDM 
was approved by the FDA in 2000 with  98% of certified mammography facilities having FFDM 
units as of June 1, 2017159. While some studies have shown an increased rate of breast cancer 
detection using FFDM52,160, the majority of studies, including the large DMIST trial161, have 
reported no difference in cancer detection rate using FFDM vs. SFM162-168 among the general 
screening population; increased cancer detection rates with FFDM may be due to higher rates of 
DCIS detection by this modality169-171. DMIST also showed that FFDM performed better among 
premenopausal women and women with dense breasts161,172. Studies using data from both 
European population-based screening programs163,173,174 and an American mammography 
registry51 have seen no difference in interval cancer rates when comparing the two screening 
technologies, although the Oslo II clinical trial found a lower interval cancer rate at FFDM vs. 
SFM175. 
With respect to subtype, among screen-detected cancers, higher rates of ER+, PR+, and 
HER2- cancers were detected using FFDM vs. SFM176; the authors also recorded increased 
detection of smaller, node-negative cancers using FFDM. Microcalcifications appears to be the 
radiologic feature that has the most potential to differ between cancers detected through FFDM 
vs. SFM. Recall rate, the percent of screening mammograms that necessitate diagnostic follow-
up, is increased when using FFDM, with women most often recalled due to microcalcifications, 
some of which proved to be benign176,177. In addition, more interval cancers presented with 
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microcalcifications at the diagnostic mammogram following screening with SFM than with 
FFDM178,179. 
1.8 Future/ alternate screening methods 
There are several supplemental/ alternate breast cancer screening methods that are in use, 
including ultrasound (US), magnetic resonance imaging (MRI), digital breast tomosynthesis 
(DBT), and molecular breast imaging (MBI). Of the alternate screening methods, US and MRI 
are the most common and are often used to supplement mammography. Both of these screening 
modalities do not involve radiation, allowing for increased use of these methods. While 
mammography results in a two dimensional image of the breast, tomosynthesis provides a quasi-
3D image that is able to bypass one major drawback to mammography, which is tumors being 
hidden by overlapping tissue. There are several studies that are currently in progress to assess the 
efficacy of DBT in cancer detection compared to mammography.  Studies have shown that 
compared to mammography, DBT is more effective in classifying both architectural 
distortion180,181 and masses181. It remains to be seen if, compared to mammography, use of these 
alternate screening methods conclusively decreases the rate of interval cancers and/or results in 
increased cancer detection among women with dense breasts. 
1.9 Summary 
The goal of any cancer screening program is to be able to detect a cancer at a point in its 
natural history where it is treatable. Although mammography has been used for the past forty 
years, it remains somewhat divisive; this controversy may in part arise due to the confusion of 
the risks and benefits of mammography. There is some concern about mammography efficacy in 
subsets of women or for some tumor subtypes. It is established that mammography is less 
accurate in women with dense breasts; the sensitivity of mammography decreases from 87% in 
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women with almost entirely fatty breasts to 63% in women with extremely dense breasts71 and 
that higher mammographic density is more often associated with interval breast cancers 63,64,182.  
It has also been noted that mammography itself may contribute to lead time bias, a spurious 
survival benefit that is seen due to the time period between screening detection of a cancer and 
clinical presentation of the cancer, and length time bias, when screening preferentially detects 
indolent tumors183 that may have never clinically manifested, leading to over-treatment. This 
comes at the price of potentially missing more aggressive, faster growing cancers that evade 
screening and have a large impact on mortality because they are detected at a more advanced 
stage than a screen-detected cancer.  
Interval cancers are a group of cancers where screening may have failed and since these 
cancers have been shown to present with worse prognostic factors than screen-detected cancers, 
they may signify a circumstance where mammographic detection can be improved. 
Mammographic density is not the only factor that can affect mode of detection; molecular 
characteristics of a cancer such as intrinsic subtype or p53 status, which can be used to describe 
cancer agressivity, may also be associated with mode of detection. Understanding the tumor 
biology of screen vs. interval vs. clinically detected cancers is therefore important as it can 
provide information on the utility of mammography and enable a better understanding of its 
benefits and limitations.  
The radiologic features of cancers [inclusive of both detection features (screen vs. 
interval-detected) and imaging features (calcifications, mass, etc.)] can potentially be used as a 
means to predict breast cancer subtype. Studies have shown that this is possible when 
categorizing cancers into broad subtypes, but it has not been used as widely with molecular 
subtypes defined using IHC and never using PAM50 derived subtypes. The population-based 
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study sample, with its racial diversity and well-characterized tumor biology, sets this study apart 
from similar studies. To better understand the limitations and public health opportunities 
surrounding breast cancer screening, it is essential to better characterize cancers that are detected 
outside of mammography. 
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CHAPTER 2: SPECIFIC AIMS 
Mammography is the most widely used breast cancer screening method with approximately 
70% of US women > 50 having had a mammogram within the past 2 years184. Among a regularly 
screening population, breast cancers can be categorized into two groups based on 
mammographic mode of detection: screen-detected cancers (SDC) and interval cancers, which 
are cancers that are detected symptomatically between regular screenings. Compared to SDCs, 
interval cancers generally have poor survival and many adverse prognostic factors91-93,185. 
Current literatures suggests that screening mammography may detect indolent cancers, and miss 
more aggressive cancers that have the greatest impact on mortality. Biologic characteristics of 
screen-detected vs interval cancers have been reported, but most previous studies with well-
characterized tumors subtyped using IHC have relatively few subjects68,118,125,138. After a cancer 
has been detected through screening or otherwise, it may be further possible to identify cancer 
subtype based on mammographic features. Some studies suggest that triple negative cancers are 
more likely to present mammographically with rounder masses and fewer calcifications 
compared to ER+ cancers142,154,186-188, although studies of these features have been small (<200 
cases) and there remains important uncertainty about the relationships between imaging features 
and subtype.  
In this study, we used a linked dataset of the Carolina Breast Cancer Study (CBCS) and the 
Carolina Mammography Registry (CMR) to study mammographic and radiologic characteristics 
by breast cancer subtype. Identification of these associations is important as it highlights 
limitations of mammographic screening.  
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Aim 1. To identify molecular and genomic characteristics of screen vs. interval-detected 
cancers in the Carolina Breast Cancer Study. 
Tumor characteristics vary according to mode of detection, with interval cancers showing 
higher grade, larger size, and lower rates of hormone receptor positivity.  However, there is 
limited data on how interval cancers relate to molecular subtype of breast cancer. Among linked 
invasive CBCS-CMR linked cases, patients were classified as screen vs. interval-detected using a 
two year screening interval. Associations between molecular and genomic characteristics (p53 
status, 3- and 5-marker IHC subtyping, PAM50 subtype and risk of recurrence score) and mode 
of detection were assessed. We hypothesized that with high mammographic density and 
aggressive tumor characteristics such as larger size, higher grade, and more aggressive molecular 
subtype (Basal, p53 positive) will be at higher risk of having an interval-detected cancer.  
Aim 2.  To estimate associations between imaging features (mass and calcifications) and 
breast cancer subtype among women with invasive breast cancers with mammograms 
recorded in CMR (N=412). 
Previous small studies (generally, N <200) have used broad categories (i.e., ER+, 
HER2+, triple negative vs. non-triple negative) to show that different tumor types present with 
different imaging features, which may affect probability of screen vs. interval detection. We 
hypothesized that calcifications, are more likely to present in screen-detected cases and in 
Luminal breast cancers and that interval cancers are more likely to present as a mass and are 
more likely to be basal-like.  
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CHAPTER 3: METHODS 
3.1 Data Sources 
3.1.1 Carolina Breast Cancer Study 
The Carolina Breast Cancer Study (CBCS) is a population-based epidemiological study 
designed to identify both genetic and environmental risk factors for breast cancer among North 
Carolina women. The current study will use data from all three phases of CBCS. The CBCS has 
a high proportion of both African-Americans and young women, allowing for a more thorough 
assessment of factors affecting mammography uptake and cancer outcomes in these groups with 
a larger sample size compared to previous studies68,73,100,118,119,189. This research within the CBCS 
resource has been approved by the University of North Carolina at Chapel Hill School of 
Medicine Institutional Review Board (IRB). 
The first two phases of CBCS recruited both cases and controls. Phases 1 and 2 recruited 
from 24 counties of eastern and central NC190. Cases were eligible women between the ages of 
20 and 74 diagnosed with a primary invasive breast cancer May 1, 1993 and December 31, 2000. 
These women were identified through rapid case ascertainment from the North Carolina Central 
Cancer Registry. Controls were obtained from NC Division of Motor Vehicles lists for women 
aged 20-64; for women 65-74, the US Health Care Financing Administration lists were used. 
Controls were frequency matched to cases by race and 5-year age group. There were 2311 cases 
and 2022 controls enrolled in both of these phases. Randomized recruitment was used to 
oversample both African American and younger cases (under age 50)114. The sampling 
proportions differed between the two phases; in Phase 1, which recruited from 1993-1996, 100% 
of younger African Americans, 75% of African Americans over the age of 50, 67% of younger 
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non-African Americans, and 20% of non-African Americans over the age of 50 were sampled190. 
In Phase 2, which recruited from 1996-2001, all African Americans, 50% of younger non-
African American, and 20% of older non-African American cases were sampled. The overall 
cooperation rate for invasive cases was 78%, with 84% for younger White cases, 80% for 
younger African American women, and 76% and 72% for older White and African-American 
women, respectively191. Overall cooperation for controls was 70%. 
Women were interviewed at baseline by a nurse, at which point they also provided 
written consent for medical record requests. At baseline, nurse-administered interviews were 
used to collect demographic and risk factor data (described below). The median time between 
diagnosis and interview for cases was 3 months, with 80% being interviewed within 5 months of 
diagnosis. For controls, median time between selection and interview was 2 months, also with 
80% being interviewed within 5 months of selection. 
Phase 3 of CBCS enrolled 3000 participants from 2008-2013. The design is similar to 
that of the previous phases except that it enrolled invasive breast cancer cases only (no controls), 
and recruited from 44 counties in NC, a larger recruitment area192. Like Phases 1&2, randomized 
recruitment was used to achieve oversampling of African Americans. The sampling fraction for 
African Americans less than 50 years old, and greater than 50 were 100% and 60% respectively. 
The sampling fractions for non-African Americans less than 50, and greater than 50 years old 
were 40% and 15%, respectively.  
3.1.2 Carolina Mammography Registry 
The CMR193 is a large community-based mammography registry that has studied the 
performance and outcomes of mammography in North Carolina since 1994. Data from the 
CMR comes from 39 practices and 65 facilities across North Carolina and is collected from 
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both patients and radiologists/technologists. Of the registries associated with the Breast 
Cancer Surveillance Consortium, the CMR has historically has the highest proportion of 
African American women. The age range of women in the CMR is 18-95 years. As of 2013, 
there were over 20,000 women diagnosed with breast cancer in the CMR194. Mammography 
records are linked to the North Carolina State Death Tapes to ascertain cause and date of 
death. 
In CMR, at the time of mammography, reason for visit, the type of any screening or 
diagnostic studies performed, and imaging findings are recorded; this is done at each imaging 
visit. Radiologists choose from one of the following options when recording the reason for 
the patient’s visit: 1) clinically detected (screening), 2) clinically detected, problem solving, 
diagnostic work-up, 3) continued work-up following abnormal mammogram or ultrasound, 
4) short-term follow-up (mostly 6 month follow-up), 5) post-cancer follow-up, 6) biopsy, or 
7) other. Next, the radiologist records the type of screening or diagnostic study that was 
performed: 1) mammogram, 2) tomosynthesis, 3) ultrasound, 4) MRI, 5) CT, 6) other. This 
information will be used when assigning women to categories of initiation, adherence, and 
mode of detection. 
Mammographic density is recorded at each mammogram. Radiologists associated 
with the CMR visually assess mammograms and assign mammographic density. The 
mammographic density categories used in this study will be based on the Breast Imaging-
Reporting and Data System (BI-RADS) breast composition categories, a standardized visual 
assessment metric that is published by the American College of Radiology195. The four BI-
RADS categories, going from least dense to most dense are: almost entirely fatty (BI-RADS 
a), scattered fibroglandular (BI-RADS b), heterogeneously dense (BI-RADS c), and 
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extremely dense (BI-RADS d). Though this measure is subjective, it has been shown to have 
high interobserver and intraobserver agreement for the two most extreme categories, though 
some misclassification exists between the two intermediate categories196,197. There has also 
been variability in mammographic density classification reported in the presence of cancer198. 
Though the potential for misclassification exists, the BI-RADS classification measures will 
be utilized for this study because of its clinical relevance. BI-RADS is the only 
mammographic density classification method currently in clinical use in the US199, making 
our study results more applicable to current clinical practice. In the CMR, mammographic 
density is not recorded for each breast, but per woman. This is acceptable for this study as it 
has been shown that mammographic density is highly correlated between breasts within a 
woman200. Because this study is concerned with how breast density is associated with breast 
cancer detection, mammographic density will be recorded using the mammogram closest in 
time to the diagnosis date, with priority being given to mammograms before diagnosis. For 
all analyses, mammographic density with be categorized as non-dense (BI-RADS 1 and 2) 
and dense (BI-RADS 3 and 4).   
The CMR is reviewed annually by the University of North Carolina Chapel Hill 
School of Medicine IRB. CMR data undergo quality control checks: missing and 
incongruous data are flagged and reports are sent to practices for verification. The major 
advantage of linkage to CMR data is the detail of mammographic data that can be obtained 
from this source; this level of detail is useful for classification of women based in their 
mammographic screening behavior. During the recruitment time period for CBCS were 
recruited, with screen-film mammography being used for participants from Phases 1&2 and 
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digital mammography primarily being used over the last decade when CBCS Phase 3 was in 
recruitment201. 
3.1.3 Carolina Mammography Registry- Carolina Breast Cancer Study Linkage 
Phases 1, 2 and 3 of CBCS (N=7331) were linked to the all participants enrolled in CMR 
from 1994-2014 inclusive (N=657,060), with a final dataset of 2,614 women (871 controls and 
1,743 cases). Figure 3.1 shows the overlapping coverage of CBCS and CMR. Due to data 
security concerns, the linkage did not include women from one large CMR facility in eastern 
North Carolina. IRB approval was obtained before data merging.  
 
The linkage was performed by experienced programmers from the Cancer Information & 
Population Health Resource (CIPHR) at UNC using the following identifiers: last four digits of 
social security number (SSN), first names, last name, middle initial, date of birth, and address. 
There were some limitations with regards to using SSN for linkage. Full security numbers were 
not available for all women in CMR and only the last 4 digits of SSN were available, so linkage 
was done using the last 4 digits. In addition, because some women in CBCS Phase 3 did not give 
permission for their SSNs to be used in any other data analysis, Phase 3 of CBCS had to be 
linked in two stages: once for those with SSN information available, and once for those without. 
The sensitivity of linkage for both stages was 100%. The specificity was 95.2% for women 
Figure 3.1 Overlap of CBCS and CMR 
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without SSN information and 97.1% for women with SSN information. Matches and non-
matches were determined using thresholds set based on linking probabilities of the identifiers 
chosen.  
Selection bias 
Selection bias was assessed in several different ways. First, selection bias between linked 
and unlinked women was first assessed (Table 3.1). Women who were linked were more likely 
to be cases, from Phase 2, older, post-menopausal, and had any hormone replacement therapy. 
No differences were seen by any other demographic variables. We also assessed if there was any 
bias related to whether social security information was available for use in linkage, and saw no 
differences by any of the variables studied (Table 3.2). Because only invasive cases were used in 
this study, we also evaluated differences in frequencies of demographic and cancer clinical 
variables comparing linked vs. unlinked invasive cases (Table 3.3). Among the linked invasive 
cases, there was a higher frequency of women over the age of 50, postmenopausal women, 
participants from Phase 2 of CBCS, and women who had ever used hormone replacement 
therapy. With respect to clinical characteristics, there was a higher frequency of higher stage 
(Stage III & IV) cancers and cancers with larger (>2 cm) tumors among the unlinked invasive 
cancers. Taking all of these selection bias analyses together, it appears that the linked women in 
our study display characteristics of an older population. This is expected as women captured in 
CMR are those who are getting mammography screening, which is generally recommended for 
women 50 and above. 
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Table 3.1 Assessment of selection bias: linked vs. unlinked women, CMR-CBCS linkage 
 
Linked 
 (N=2614) 
Unlinked 
(N=4717) 
Χ2 p 
 
N (%) N (%)  
Case/control 
  
 
       Control  871 (33.3) 1151 (24.4)  
       Case    1743 (66.7) 3566 (75.6) <0.0001 
Phase of study    
Phase 1  583 (22.3) 1068 (22.6)  
Phase 2 1148 (43.9) 1534 (32.5)  
Phase 3  883 (33.8) 2115 (44.8) <0.0001 
Race 
  
 
White 1497 (57.3) 2657 (56.3)  
        Black    1117 (42.7) 2060 (43.7) 0.4 
Age at selection/ 
diagnosis 
  
 
         <35     87 ( 3.3)  266 ( 5.6)  
         35-54 1361 (52.1) 2698 (57.2)  
55-64  658 (25.2)  918 (19.5)  
65-74  508 (19.4)  835 (17.7) <0.0001 
Menopausal status      
         Pre 1037 (39.7) 2211 (46.9)  
         Post 1577 (60.3) 2506 (53.1) <0.0001 
Marital status    
Never married        255 ( 9.8)  461 ( 9.8)  
Married             1613 (61.7) 2750 (58.3)  
Widowed             277 (10.6)  504 (10.7)  
Separated, divorced  468 (17.9) 1001 (21.2) 0.01 
Missing    1    1  
Education    
< High school         365 (14.0)  614 (13.0) 0.2 
High school & Post 
High school 
1430 (54.7) 2531 (53.7)  
≥ College      819 (31.3) 1569 (33.3)  
Missing    0    3  
Family income    
<15K    420 (17.3)  891 (20.2) 0.03 
15-30K  537 (22.1)  926 (21.0)  
30-50K  552 (22.8)  950 (21.5)  
>50K    916 (37.8) 1645 (37.3)  
Missing  189  305  
Family history    
No  2102 (83.0) 3815 (83.2)  
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Yes  431 (17.0)  768 (16.8) 0.8 
Missing   81  134  
Any hormone 
replacement therapy 
   
Never 1753 (67.1) 3488 (74.1)  
Ever   858 (32.9) 1217 (25.9) <0.0001 
Missing    3   12  
 
Table 3.2 Assessment of selection bias among linked invasive cases from Phase 3 of CBCS: 
linkage with SSN vs. linkage without SSN 
  Social security 
information 
available 
(N=399) 
Social security 
information  not 
available (N=461) 
Χ2 p-value 
 N (%) N (%)  
Race 
  
 
White 214 (54) 221 (47)  
Black 185 (46) 248 (53) 0.06 
Age 
  
 
<50 247 (62) 275 (59)  
≥50 152 (38) 194 (41) 0.3 
Education 
  
 
< High school  201 (50) 249 (53)  
≥ High school 198 (49) 220 (47) 0.4 
Income 
  
 
< 30K 145 (38) 174 (40)  
>30K 26 (62) 261 (60) 0.6 
Missing 18 34  
Family history    
No 294 (76) 366 (81)  
Yes 95 (24) 88 (20) 0.08 
Missing 10 15  
Menopausal status    
Pre 138 (35) 179 (38)  
Post 261 (65) 290 (62) 0.3 
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Table 3.3 Assessment of selection bias of clinical cancer characteristics of linked vs. unlinked 
invasive cases. 
 
Linked invasive 
cases (N=1497) 
Unlinked invasive 
cases (N=3309) 
Χ2 p-
value 
 N (%) N (%)  
Age at diagnosis 
   
<35   62 ( 4) 201 ( 6) <0.0001 
35-44 276 (18) 882 (27) 
 
45-54 489 (33) 1053 (32) 
 
55-64 386 (26) 640 (19) 
 
65-74 284 (19) 533 (16) 
 
Race 
   
White 788 (53) 1735 (52) 0.9 
African-American     709 (47) 1574 (48) 
 
Phase of study 
   
Phase 1 252 (17) 609 (18) <0.0001 
Phase 2 377 (25) 570 (17) 
 
Phase 3 868 (58) 2130 (64) 
 
Menopausal status 
  
Premenopausal  590 (39) 1627 (49) <0.0001 
Postmenopausal 907 (61) 1682 (51) 
 
Marital status 
   
Never married       178 (12) 367 (11) 0.1 
Married             881 (59) 1867 (56) 
 
Widowed             143 ( 10) 318 ( 10) 
 
Divorced 295 (20) 756 (23) 
 
Missing 0 1 
 
Family income 
   
<15K   237 (17) 628 (20) 0.06 
15-30K 308 (22) 628 (20) 
 
30-50K 289 (21) 649 (21) 
 
>50K   568 (41) 1211 (39) 
 
Missing 95 193 
 
Education 
   
< HS         189 (3) 380 (12) 0.3 
HS & Post HS 801 (54) 1746 (53) 
 
College+     507 (34 1182 (36) 
 
Missing 0 1 
 
First degree family history of breast 
cancer 
  
No  1174 (81) 2624 (82) 0.5 
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Yes 277 (19) 583 (18) 
 
Missing 46 102 
 
Any hormone replacement therapy 
  
Never 1059 (71) 2574 (78) <0.0001 
Ever  435 (29) 723 (22) 
 
Missing 3 12 
 
Tumor size 
   
<=2 cm  799 (55) 1623 (51) 0.02 
>2-5 cm 507 (35) 1165 (37) 
 
>5 cm   143 (10) 381 (12) 
 
Missing 48 140 
 
AJCC/UICC Stage Grouping 
  
Stage I   645 (45) 1289 (40) 0.0007 
Stage II  611 (42) 1360 (42) 
 
Stage III 159 (11) 436 (14) 
 
Stage IV  34 ( 2) 126 (4) 
 
Missing 48 98 
 
IHC subtype 
   
Present 427 (29) 722 (22) <0.0001 
Missing 1070 (72) 2587 (78) 
 
IHC subtype 
   
Basal-like   72 (17) 133 (18) 0.9 
Luminal A    241 (56) 384 (53) 
 
Luminal B    39 ( 9) 73 (10) 
 
HER2+/ER-    27 ( 6) 46 ( 6) 
 
Unclassified 48 (11) 86 (12) 
 
Missing 1070 2587 
 
ER Status 
   
Positive   915 (63) 2088 (66) 0.1 
Negative   496 (34) 999 (31) 
 
Borderline 36 ( 3) 92 ( 3) 
 
Missing 50 130 
 
PR Status 
   
Positive   762 (53) 1746 (55) 0.005 
Negative   614 (43) 1214 (38) 
 
Borderline 67 ( 5) 203 ( 6) 
 
Missing 54 146 
 
HER2 Status 
   
Positive 206 (15) 480 (16) 0.4 
Negative 1146 (85) 2474 (84) 
 
Missing 145 355 
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 The exclusion criteria applied in this study are shown in Figure 3.2. As a secondary 
quality control measure for the linkage, 
information from one commonly collected 
variable between the two data sets, date of 
diagnosis, was compared. Both CBCS and CMR 
collected data for this variable from the NC 
Central Cancer Registry, so date of diagnosis 
should therefore be the same if the match from 
the linkage was correct. There were 15 women 
where dates of diagnosis did not match, and 
these women were excluded from analysis. The 
final data set that was used for this dissertation 
contained 1497 women. 
3.1.4 Data Acquisition 
Letters of intent were filed with both CBCS and CMR before the linkage was done. The 
linkage was approved by the Institutional Review Board (IRB) at the University of North 
Carolina at Chapel Hill (IRB# 14-2263). A separate proposal for this study was approved by the 
UNC IRB (IRB# 16-2104).  
3.2 Data Analysis 
3.2.1 Mode of detection categorization 
 Mode of detection was constructed using both CMR and CBCS data and was used to 
classify how breast cancer was detected. We initially categorized mode of detection into 
three groups: screen-detected, interval-detected, or clinically detected, based on standard 
Figure 3.2 Flowchart showing exclusion criteria. 
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definitions for mode of detection. However, due to likely missing data and heterogeneity 
within the clinically-detected group, this group was later renamed as “unknown” mode of 
detection and excluded from all analyses. In this section mode of detection categorization 
will be defined as it was originally planned.   
 The date of the last screening mammogram before diagnosis in combination with the 
date of breast cancer diagnosis was used to assign mode of detection. The date of breast 
cancer diagnosis was taken from CBCS data. A screening mammogram was defined using 
the definition constructed by the BCSC. The BCSC considered a mammogram to be 
screening if the indication for the exam is routine screening, a mammogram exam was done, 
the first exam sequence of the day, the woman was 18 or older, had no breast implants or 
prior mastectomy, bilateral screening views were done, there was no history of breast cancer 
cased on self-report or in the analytic cancer file, there was no imaging in the previous 9 
months in the database or based on self-report, radiologist report, or comparison film, and the 
overall assessment code was not BI-RADS 6. 
 The mammogram findings are recorded in CMR, using BI-RADS assessment 
categories202, as shown in Table 3.4; it is important to note that these categories are different 
from the BI- RADS categories that are used to describe mammographic density. Our 
definitions for classifying how breast cancer was detected use the outcome of a screening 
mammogram, more specifically, whether it was positive or negative. A positive screening 
mammogram will be defined as a screening mammogram with a BI-RADS assessment code 
of 4 (suspicious abnormality), 5 (highly suggestive of malignancy) or 0 (incomplete) or 3 
(probably benign finding) with a recommendation for biopsy, fine needle aspiration (FNA), 
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or surgery. A negative screening mammogram will be defined as a screening mammogram 
with a BI-RADS assessment category of 1, 2, or 3 with no recommendation for biopsy, fine  
needle aspiration (FNA), or surgery.  
 As described earlier and as shown 
in Appendix A, screening 
recommendations greatly varied from 
organization to organization and from year 
to year over all 3 phases of CBCS; 
recommendations were for 1 year, 2 year, 
and 1-2 year screening intervals. The 2-
year interval was chosen for constructing 
the main mode of detection variable for 
this analysis in order to increase comparability with other studies and to reflect current 
screening recommendations, although a 1 year interval was used to construct the mode of 
detection variable that was used in sensitivity analyses. Figure 3.3 visually demonstrates the 
classification scheme that was originally used to categorize women by mode of detection. 
The following definitions were used to classify cancers: 
 Screen-detected. Cancer diagnosed within 24 months after a positive screening 
mammogram.  
 Interval-detected. Cancers diagnosed within 24 months after a negative screening 
mammogram and prior to the next screening mammogram, among women with no self-
reported symptoms at time of screening mammogram. 
Category Description 
Likelihood of 
Malignancy 
0 Incomplete Unknown 
1 Negative 0 
2 
Benign 
finding 
0 
3 
Probably 
benign 
finding 
<2% 
4 
Suspicious 
abnormality 
12-25% 
5 
Highly 
suggestive of 
malignancy 
>95% 
6 
Known 
biopsy- 
proven 
malignancy 
100% 
Table 3.4 BI-RADS assessment categories. 
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 Clinically detected.  Women in this group are women who did not have a screening 
mammogram within 24 months of breast cancer diagnosis, and were not classified as screen-
detected or interval-detected. This category includes women whose breast cancers were 
detected by themselves or by a clinician. This group was renamed “unknown” mode of 
detection and excluded in final analyses. 
 
 
To check the coding of the mode of detection variable, the variable constructed for this 
study was compared against the BCSC computed variable. The classification algorithm that the 
BCSC used is shown below, in Figure 3.4. One notable difference between the classification 
schemes used to construct the main mode of detection variable in this study vs. in BCSC is 
BCSC’s use of a “peri-cancer” mammogram for further classification of some interval and 
clinically detected cancers. In addition, the BCSC classification schema also includes an 
“unknown” group. Table 3.5 shows the frequencies of the BCSC variable along with frequencies 
Figure 3.3 Mode of detection classification flowchart 
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for the mode of detection variable constructed using the 1 year screening interval and the 2 year 
screening interval. The frequency of screen-detected cancers is similar for all 3 variables (11-
12%). The interval cancer counts from the 2 year interval variable are very similar to the BCSC 
variable, which is based on a 1 year interval, but they should in fact be approximately double the 
BCSC count since the time interval is twice as long. The BCSC definition includes an additional 
way to classify interval cancers, using the peri-cancer mammogram; when examining the full 
breakdown of the BCSC “interval” group, the interval cancers that were classified using the peri-
cancer mammogram accounted for about 50% of interval cancers. Since the peri-cancer 
mammogram was not used for the variable used in this study, this would account for why the 
study variable interval cancer counts are approximately half of those from the BCSC. 
 
 
 
 
Figure 3.4 BCSC mode of detection classification. 
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Table 3.5 Comparison of frequencies of mode of detection variable. 
  1 year interval 
N (%) 
2 year interval 
N (%) 
BCSC (1 year) 
N (%) 
Screen-detected 161 (11) 165 (11) 176 (12) 
Non-screen-detected 1336 (89) 1332 (89) 295 (20) 
Interval 107 (7) 205 (14) 196 (13) 
Clinically detected 1229 (82) 1127 (75) 99 (7) 
Unknown     1026 (69) 
 
CBCS 
3.2.2 Clinical and molecular variables 
All clinical tumor variables that were used are described in Table 3.6. Histological grade 
was determined by a CBCS study pathologist. All variables in the table below are available in all 
3 phases of CBCS. Tumor size, nodal status, and stage were abstracted from medical records. ER 
and PR status were determined from medical record abstract and from IHC staining; women with 
values that were borderline had their status set to missing. HER2 status was determined using 
IHC only for Phases 1&2. In Phase 3 of CBCS, HER2 status was determined using IHC and 
FISH. Women who were positive, negative, or borderline by IHC and were missing FISH status 
were classified using IHC HER2 status. Women who were either missing or borderline for IHC 
HER2 status, but had FISH results were assigned the FISH status. Women who were either 
positive for both IHC and FISH or negative for both IHC and FISH were assigned the IHC 
status. When women did not have an IHC HER2 status that matched FISH status, but FISH 
status was positive, these women were classified as HER2 positive; otherwise HER2 status was 
set to missing. 
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Table 3.6 CBCS clinical tumor variables 
Variable Description/ Code in statistical analysis 
Tumor size Categorized as ≤ 2 cm and >2 cm 
Nodal status Categorized as positive and negative. Positive is defined as 
either having at least one node positive for malignancy or 
lymph node metastasis. 
Stage Based on AJCC/UICC Stage grouping, categorized as: 
1) Stage I & Stage II 
2) Stage III & Stage IV 
ER status Categorized as positive/negative. 
PR status Categorized as positive/negative. 
HER2 status Categorized as positive/negative. 
 
Subtype definitions  
IHC  
Because CBCS data is more comprehensive, all breast cancer subtype data came from the 
CBCS dataset, despite the availability of limited histologic and molecular data in the Carolina 
Mammography Registry. Approximately 64% (N=1149) of enrolled Phase 1&2 CBCS women 
had sufficient tissue for IHC analysis114, with a similar proportion of women in CBCS Phase 3 
(1888/2998=63%). Among women in Phases 1&2, there are a few significant differences 
between women with and without sufficient tissue: women with sufficient tissue had a higher 
proportion of African-American women, later stage at diagnosis114 and larger tumors111. In 
CBCS Phases 1&2, the tumor tissue was sectioned and stained at the Immunohistochemistry 
Core Laboratory (ICL) at the University of North Carolina. A single pathologist reviewed all 
slides to confirm diagnosis of breast cancer and to assign tumor histology 203. The following IHC 
markers were used to distinguish intrinsic subtype: estrogen receptor (ER), progesterone receptor 
(PR), human epidermal growth factor-2 (HER2), human epidermal growth factor-1 (HER1), and 
cytokeratin 5/6 (CK5/6). Previously described assays were used for these IHC markers111,204,205. 
ER and PR status were determined from medical records for the 80% of women who had this 
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data available from medical records204; for the remaining cases with paraffin-embedded tissue 
available, IHC analysis was performed at the Immunohistochemistry Laboratory. Positivity for 
ER and PR status were defined as having more than 5% of cells showing nuclei-specific 
staining111. Tumors with HER2 staining in more than 10% of cells were considered HER2 
positive205.  Positivity of EGFR was defined as any HER1 staining and positivity for CK 5/6 was 
defined as any cytoplasmic and/or membranous staining117. Previously identified IHC profile 
proxies for intrinsic subtypes are shown in Table 3.7111,206.  
For Phase 3, paraffin-embedded tumor blocks were used for tissue microarray (TMA) 
construction128. These TMAs were stained for ER, PR, HER2, Ki67, CK5/6, and EGFR by IHC, 
and digitally quantified using digital image analysis as described by Allott et al128.  
Table 3.7 IHC markers used to classify subtypes  
 
 
 
Intrinsic 
subtype 
IHC profile 
for clinical 
subtype (3 
marker) 
IHC profile for 
Phases 1 & 2 
IHC profile for Phase 3 
Luminal A HER2-, ER+ 
and/or PR+ 
HER2-, ER+ 
and/or PR+ 
ER+, PR ≥ 20%, HER2-, 
AND Ki67 <10% 
Luminal B HER2+, ER+ 
and/or PR+ 
HER2+, ER+ 
and/or PR+ 
ER+, PR≤20%, HER2-, 
AND Ki67 ≥10% OR 
ER+, PR ≥10%, HER2-, 
AND Ki67 ≥10% 
Triple 
negative 
HER2-, ER-, 
PR- 
HER2-, ER-, 
PR- 
HER2-, ER-, PR- 
Basal-like  HER2-, ER-, 
PR-, EGFR+ 
and/or CK 5/6+ 
(ER- AND PR- AND 
HER2-) AND (EGFR ≥ 
1% OR CK5/6 ≥ 1%) 
HER2+/ER- HER2+, ER-, 
PR- 
HER2+, ER-, 
PR- 
ER- AND HER2 positive 
Unclassified N/A ER-, PR-, 
HER2-, EGFR-, 
CK 5/6- 
Equivocal HER2 or 
missing biomarker status 
for one or more markers 
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PAM50 
 PAM50 subtyping was performed on a subset (n=2007) of samples from CBCS 
Phases 1-3; 32% of these women (N=644) were among the invasive cases in the linked 
CBCS-CMR data set. For samples from CBCS 1&2 (N=188), RNA was extracted from two 
unstained 10-µM FFPE slides per patient. For women in CBCS Phase 3, RNA was extracted 
from cores (N=377) and slides (N=79). As described previously, for women with cores 
available, RNA was extracted from two flash frozen 1.0-mm cores taken from paraffin-
embedded tumor blocks that were pooled for analysis128. For women who did not have cores 
available, two unstained 4-µM FFPE biopsy slides were used per patient for RNA extraction.  
Extracted RNA was isolated using the RNEasy FFPE Kit (Qiagen) and Nanostring analyses 
were performed in the Rapid Adoption Molecular laboratory at UNC.  
 All CBCS Phase 1&2 samples were run using a Nanostring probe set of 417 genes 
and the majority of CBCS Phase 3 samples were run using a probe set of 200 genes. Both 
code sets contained the 50 genes that make up the PAM50 group of genes. Tumors were 
classified as luminal A, luminal B, HER2-enriched, basal-like, and normal-like using the 
PAM50 predictor127. 
 RNA gene expression for p53 mutation status was determined using a previously 
published 52-gene p53 signature207. A different subset of the PAM50 genes were also used to 
construct the risk of recurrence score, taking into account proliferation and tumor size (ROR-
PT)208. The ROR-PT score is the research correlate of the clinically used Prosigna assay 
(NanoString Technologies Inc., Seattle, WA, USA), which has been clinically validated209. 
The ROR-PT is a continuous score, but can be categorized (Low/Medium/High) using 
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published protocols127. In this data set, the ROR-PT score was correlated with both PAM50 
subtype and p53 status. 
 Selection bias analysis was done among the linked invasive cases that were included 
for analysis (N=1497) to ascertain any differences between the group of women that had 
RNA data available (N-644) vs. those who did not (N=853) (Table 3.8). The only difference 
that was seen was with respect to CBCS recruitment phase, with a smaller proportion of 
women from the early phases of CBCS 1&2 having genomic data available. 
Table 3.8 Assessment of selection bias among women with and without genomic data available 
 Genomic data 
available 
(N=644) 
No genomic 
data 
(N=853) 
Χ2 p 
CBCS Phase    
1&2 188 (29) 441 (52)  
3 456 (71) 412 (48) <0.0001 
Race    
White 323 (50) 465 (55)  
Black 321 (50) 388 (45) 0.1 
Age    
<50 369 (57) 474 (56)  
≥50 275 (43) 379 (44) 0.5 
 
p53 
 p53 status was assigned based on both IHC data (Phases 1-3 of CBCS) and RNA 
(Phase 3) data. p53 positivity for IHC was defined as dark nuclear protein staining present in 
10% or more of invasive cells, all other cases were considered p53 negative210. While an 
IHC-based method for p53 classification is more widely used due to its relative ease, it 
cannot detect all of the types of p53 mutations that RNA-based methods are able to. For 
Phase 3, we will have both p53 data derived from both IHC and RNA. p53 classification was 
compared using both methods in CBCS3 (Williams et al., in preparation) and it was found 
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that there was increased misclassification of p53 mutant status when using IHC methods 
compared to RNA; 20% of cases were found to be p53 mutant using IHC methods whereas 
41% were mutant according to RNA-based methods.  
3.2.3 Imaging feature categorization 
 
All mammography data used in this analysis came from CMR. The indication for the 
study (screening/diagnostic/ follow-up), breast composition, important findings (imaging 
features), and final assessment (negative, benign, etc.) are recorded for each imaging exam. BI-
RADS classifications, which can be used to predict malignancy211-213, for each imaging feature 
are noted by the radiologist for each imaging exam performed. Imaging features used in this 
analysis were mass and calcifications. Architectural distortion and asymmetry were not used due 
to low prevalence in our study sample. All data on these features were extracted from the most 
recent diagnostic exam (recorded within two years before to 30 days after diagnosis) when 
possible. Data from the most recent (within two years before diagnosis) screening mammogram 
was used for women who did not have diagnostic exam data available. Due to power 
considerations, imaging features were categorized dichotomously. A feature was considered 
“absent” when BI-RADS=1; a feature was categorized as “present” when BI-RADS=2, 3, 4, or 
5. Imaging features with BI-RADS=0 were excluded. The imaging feature variables used in 
analysis were any mass (mass ± calcifications), any calcifications (calcification ± mass), and 
mass only (mass without calcifications). Presence of any mass was the most common (49%), 
followed by mass only (42%), and any calcifications (20%). 
 Selection bias analysis was done among the linked invasive cases that were included 
for analysis (N=1497) to ascertain any differences between the group of women that had 
imaging data available (N=412) vs. those who did not (N=1085) (Table 3.9). The only 
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difference that was seen was with respect to CBCS recruitment phase, with the majority of 
women that had imaging data available being from the first 2 phases of CBCS.  
  Missing data 
N (%) 
Included in analysis 
N (%) 
p 
Age    
≥ 50 621 (57) 222 (54) 
 
< 50 464 (43) 190 (46) 0.2 
Race    
White 584 (54) 204 (50) 
 
Black 501 (46) 208 (50) 0.2 
CBCS Phase    
1&2 358 (33) 271 (66)  
3 727 (67) 141 (34) <0.0001 
 
3.2.4 Demographics/ confounders 
The demographic information that was used in analyses are presented in Table 3.10. 
These variables were chosen based on the literature and the data available in the data set. Though 
the CMR collected demographic information, all demographic data to be used in analyses, was 
taken from the CBCS dataset for consistency. This information was collected during the nurse 
administered in-person interviews. All measures were self-reported, but BMI was nurse-
measured. Women who are not White or African-African American will be excluded, as we will 
not have enough power to detect any associations in these smaller racial groups. 
 
 
 
 
 
Table 3.9 Assessment of selection bias among women with and without imaging feature data 
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Table 3.10 Description of demographic variables. 
Variable Description/ code in statistical analysis 
Age at diagnosis <50 
50-74 
Race White 
African-American 
BMI Underweight (BMI < 18.5) 
Normal weight (18.5 ≤ BMI < 25) 
Over weight (BMI ≥ 25) 
First degree family history of 
breast cancer 
Yes 
No 
Highest level of education 
completed 
< High school 
≥ High school 
Family income < $30,000 
≥ $30,000 
Menopausal status Premenopausal 
Postmenopausal 
Marital status Married 
Single 
Widowed/ divorced 
Oral contraceptive use Ever (current or former) or never 
Hormone replacement 
therapy use 
Ever (current or former) or never 
 
Because mammographic density can change for a variety of reasons (e.g., age, parity, 
HRT use), a sensitivity analysis was performed to see how changing the time interval used to 
assign mammographic density status affected results. Four different density variables were made 
using different time intervals before/after diagnosis. These time intervals are: ≤ 5 years before 
diagnosis, ≤ 10 years before diagnosis, ≤ 5 years before or after diagnosis, and ≤ 10 years before 
or after diagnosis. Univariate analyses were done comparing associations between each MD 
variable and mode of detection (Table 3.11). All four definitions of mammographic density 
yielded similar distributions and associations with mode of detection (Table 3.12). Using this 
information, mammographic density using Definition 4 was used for all analyses. 
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Table 3.11 Definitions used to construct mammographic density variables. 
 Definition 1 Definition 2 Definition 3 Definition 4 
 Women with MD 
info < 5 years 
before diagnosis 
(N=642) 
Women with MD 
info < 10 years 
before diagnosis 
(N=884) 
Women with MD 
info 
± 5 years of 
diagnosis (N=962) 
Women with MD 
info ± 10 years of 
diagnosis 
(N=1241) 
Density     
1 32 (5) 39 (4) 43 (4) 52 (4) 
2 233 (36) 299 (34) 378 (39) 468 (38) 
3 311 (48) 451 (51) 455 (47) 608 (49) 
4 66 (10) 95 (11) 86 (9) 113 (9) 
 
Table 3.12 Associations between each density variable and mode of detection. 
  Definition 1 Definition 2 Definition 3 Definition 4 
Interval vs. 
screen-
detected 
1 year 1.9 (1.1, 3.2) 2.0 (1.2, 3.3) 2.1 (1.2, 3.4) 2.1 (1.3, 3.5) 
 2 year 1.7 (1.1, 2.7) 1.8 (1.2, 2.8) 1.7 (1.1, 2.7) 1.9 (1.2, 2.9) 
 
3.2.5 Statistical methods 
 
Clinically detected women were excluded from all analyses because this group is likely 
to be heterogeneous due to misclassification. Imaging facility participation in the CMR is 
voluntary. We do not have full mammography records for all women in this study owing to the 
fact that not all imaging facilities in NC participate. This missing information would likely lead 
to misclassification of mode of detection, with estimates of clinically detected cancers likely to 
be inflated by including both screen and interval-detected women. Due to the study definition of 
clinically detected cancers, women for whom we are missing screening information were 
classified as clinically detected because any cancer detected will appear to occur more than two 
years after screening. Therefore, clinically detected women were excluded since associations 
derived using this group most likely will not reflect true clinically detected cancers (cancers 
diagnosed among mammography non-imitators, or irregular screeners). 
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In Aim 1, t-tests were used to compare mammography usage characteristics by 
demographic characteristics. Potential confounders were chosen based on a review of the 
literature and a directed acyclic graph (Figure 3.5). Logistic regression was used to calculate 
univariate odds ratios for associations for each of the demographic variables (e.g. age, race, 
mammographic density) with mode of detection, with screen-detected cancers being used as the 
referent group. Adjusted odds ratios were then calculated for the association between clinical and 
molecular variables and mode of detection; odds ratios were adjusted for patient variables found 
to be significant in the univariate analysis.  
Because mammographic density was considered a potential effect measure modifier of 
the relationship between patient and cancer characteristics and mode of detection, all analyses 
were repeated stratifying for mammographic density. Due to the large proportion of African-
American women in our study sample, we also stratified analysis in Aim 1 by race, since race-
stratified analyses are not commonly reported. Odds ratios whose 95% confidence intervals did 
not contain the null value of 1 were considered to be statistically significant. 
For Aim 2, chi-square tests were used to study differences in mammographic feature 
presentation by patient, clinical, molecular, and genomic factors. Prevalence differences and 
their associated 95% confidence intervals were calculated using generalized linear models. 
Because differences in frequencies of imaging features were observed by CBCS phase of study, 
all prevalence difference analyses were adjusted for CBCS phase.  All analyses in both aims 
were performed using SAS version 9.3 (SAS Institute, Cary, NC). 
 
 
 
 
Figure 3.5 Directed acyclic graph 
4
7
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CHAPTER 4: MOLECULAR AND GENOMIC CHARACTERISTICS OF INTERVAL 
BREAST CANCERS 
4.1 Overview 
Introduction: Breast cancers detected after a negative breast screening exam and prior to 
the next scheduled screening are referred to as interval cancers. These cancers generally have 
poor clinical characteristics compared to screen-detected cancers, but associations between 
interval cancer and genomic cancer characteristics are not well understood.  
Methods: Mammographically-screened women who were diagnosed with a primary 
invasive breast cancer from 1993-2013 (n=370) were identified by linking the Carolina Breast 
Cancer Study and the Carolina Mammography Registry. Among women with a registry-
identified screening mammogram 0-24 months before diagnosis, cancers were classified as 
screen-detected (N=165) or interval-detected (N=205). Using logistic regression, we examined 
the association of mode of detection (interval- or screen-detected) with cancer characteristics 
(tumor size, stage, and clinical, IHC, and genomic biomarkers), overall, and in analyses stratified 
on mammographic density and race. 
Results: Interval cancer was associated with large tumors > 2 cm) (OR=2.3; 95% C.I.: 
1.5, 3.7), positive nodal status (OR=1.8; 95% C.I.: 1.1, 2.8), and triple negative cancer (OR=2.5; 
95% C.I.: 1.1, 5.5).  Associations between interval detection and genomic characteristics were 
strong, with interval cancers more likely to have non-Luminal A subtype (OR=2.9; 95% C.I.: 
1.5, 5.7). Results suggested that the vast majority of screen-detected cancers were indolent (96% 
had low risk of recurrence genomic scores; 71% were PAM50 Luminal A). When stratifying on 
race and mammographic density, associations between interval detection and poor prognostic 
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features were somewhat stronger among women with low mammographic density and among 
black women, although there were no significant interactions. 
Conclusions: Strong associations between interval cancers and both non-Luminal A 
subtype and high risk of recurrence score provide genomic evidence supporting that aggressive 
tumor biology is an important contributor to interval cancer rates.   
4.2 Introduction 
The purpose of screening is to diagnose cancer at an earlier more treatable stage, thereby 
reducing mortality9,10. Mammography, the most widely used breast cancer screening method, has 
been shown to reduce breast cancer mortality in both randomized control trials11,12 and 
population-based screening programs13,14. However, mammography remains controversial. 
Interval cancers, which represent a failure of mammographic screening, are defined as cancers 
detected after a negative mammogram in the interval between regular screenings. These cancers 
tend to be higher stage and grade at the time of diagnosis whereas screen-detected cancers have 
been reported to have more indolent molecular characteristics91-93,185. The proportion of interval 
cancers in screened populations varies from 14% to 38%47-54, depending on screening interval 
and underlying population breast cancer incidence rates214.   
Interval cancers are believed to arise from multiple scenarios. First, interval cancers may 
be cancers that existed but were missed at screening (false negatives). Some missed tumors are 
believed to be caused by masking bias, wherein high mammographic density can conceal a 
tumor from being detected, leading to false negative interval cancers72,215. Second, interval 
cancers may represent cancers that possess aggressive cancer characteristics that enable them to 
grow to detectable levels between screenings. Understanding how biologic characteristics and 
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masking contribute to the rate of interval cancer could help in understanding the limitations of 
mammography, particularly in light of emerging new technologies, like 3D-mammography.  
In this study, we used a population-based study sample to examine the molecular 
characteristics (immunohistochemical and RNA-based) of interval cancers.  Previous studies 
have shown that interval cancers have a more aggressive profile with respect to clinical factors 
such as estrogen receptor, progesterone receptor, or HER2-status48,67,91, but only one study has 
reported associations between interval cancer and RNA-based genomic subtype such as the 
PAM50 intrinsic subtype129. No study has reported associations for the genomic risk of 
recurrence (ROR-PT) score based on PAM50.  Given that genomic tests are increasingly utilized 
in clinical settings, it is important to understand the relationship of interval detection to these 
genomic characteristics. 
4.3 Methods 
4.3.1 Data Sources 
Carolina Breast Cancer Study 
The Carolina Breast Cancer Study (CBCS) is a population-based study designed to 
identify both genetic and environmental risk factors for breast cancer among North Carolina 
women190. The current analysis uses data from all three study phases of CBCS (Phase 1, 1993-
1996; Phase 2, 1996-2001; and Phase 3, 2008-2013). Randomized recruitment was used to 
oversample both African American and younger cases (under age 50)114,192 in all phases. The 
first two phases of CBCS recruited both cases and controls from 24 counties of eastern and 
central NC190. Cases were women aged 20 to 74 diagnosed with a primary invasive breast cancer 
between May 1, 1993 and December 31, 2000 and identified through rapid case ascertainment 
from the North Carolina Central Cancer Registry. Cases of in situ cancer were also enrolled in 
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Phase 2. There were a total of 2311 cases (1803 invasive cases, 508 in situ cases) enrolled in 
Phases 1&2. Phase 3 recruited cases only (N=3000) from 44 counties in NC192. 
CBCS Variables 
 Women in CBCS were interviewed at baseline by a nurse, at which point they also 
provided written consent for medical record requests. All measures were self-reported, except 
BMI, which was nurse-measured. All demographic (age at diagnosis, race, menopausal status, 
education, income, first degree family history of breast cancer, marital status, and hormone 
replacement (HRT) use), clinical (tumor size, nodal status, and stage), and molecular data used in 
this study came from CBCS. 
The following IHC markers were used to distinguish intrinsic subtype: estrogen receptor 
(ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), human epidermal 
growth factor-1 (HER1), and cytokeratin 5/6 (CK5/6), and tumor suppressor p53 (p53). 
Previously described assays were used for these IHC markers111,204,205. ER and PR status were 
determined from medical records for the 80% of women who had this data available from 
medical records204; for the remaining cases with paraffin-embedded tissue available, IHC 
analysis was performed at the University of North Carolina Translational Pathology Laboratory. 
Positivity for ER and PR status were defined as having more than 5% of cells showing nuclei-
specific staining111. Tumors with HER2 staining in more than 10% of cells were considered 
HER2 positive205.  Positivity of EGFR was defined as any HER1 staining and positivity for CK 
5/6 was defined as any cytoplasmic and/or membranous staining117. Previously identified IHC 
definitions for intrinsic subtypes were used111,206. p53 positivity for IHC was defined as dark 
nuclear protein staining present in 10% or more of invasive cells, all other cases were considered 
p53 negative210. 
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 PAM50 gene expression subtyping was performed on a subset (n=2007) of samples 
with available formal-fixed paraffin embedded cores or unstained slides from CBCS Phases 
1-3. For samples from CBCS 1&2 (N=188), RNA was extracted from two unstained 10-µm 
FFPE slides per patient. For women in CBCS Phase 3, RNA was extracted from 2 1-mm 
cores (N=377) or 2-10 um slides (N=79) as described previously128. RNA was isolated using 
the RNEasy FFPE Kit (Qiagen) and Nanostring analyses were performed in the Rapid 
Adoption Molecular laboratory and the Translational Genomics laboratory at UNC. Tumors 
were classified as Luminal A, Luminal B, HER2-enriched, Basal-like, and normal-like using 
the PAM50 predictor127. RNA gene expression for p53 mutation status was determined using 
a previously published 52-gene p53 signature207. A subset of the PAM50 genes were also 
used to construct the risk of recurrence score, taking into account proliferation and tumor size 
(ROR-PT)208. The ROR-PT is the research correlate to the clinically used Prosigna assay 
(NanoString Technologies Inc., Seattle, WA, USA), which has been clinically validated209. 
The ROR-PT is a continuous score, but can be categorized (Low/Medium/High) using 
published protocols127. 
Carolina Mammography Registry 
The Carolina Mammography Registry ( CMR)193 is a large community-based 
mammography registry that has studied the performance and outcomes of mammography in 
North Carolina since 1994 and participates in the Breast Cancer Surveillance Consortium 
(BCSC)216. The CMR collects data from breast imaging facilities across North Carolina. Data 
from patients and radiologists include patient demographics, prior screening history, breast 
cancer risk factors including family history of breast cancer, radiologist reported breast density 
using BI-RADS, reason for the visit, screening and diagnostic procedures performed, and 
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radiologists’ interpretation of the exam using BI-RADS assessment categories and the 
recommend follow-up.  
CMR Variables 
All mammography data used in this analysis, including mammographic density, type of 
exam, screening dates, and screening outcomes came from the CMR. Mammographic density is 
recorded at each mammogram by CMR. For all analyses, mammographic density will be 
categorized as non-dense (BI-RADS 1 and 2) and dense (BI-RADS 3 and 4)217.   
Mammogram findings were reported by the radiologists in CMR using BI-RADS 
assessment categories, which are different from BI-RADS density categories202. Screening 
mammograms and results were defined using BCSC definitions218. A mammogram is considered 
to be screening if: the woman was 18 or older, had no breast implants or prior mastectomy, no 
history of breast cancer, the indication for the exam was routine screening, it was the first exam 
sequence of the day, bilateral screening views were done, there was no imaging in the previous 9 
months, and the overall assessment code was not BI-RADS 6. A positive screening mammogram 
is defined as a screening mammogram with a BI-RADS assessment code of 4 (suspicious 
abnormality) or 5 (highly suggestive of malignancy). Screening mammograms with a BI-RADS 
assessment code of 0 (incomplete) with a recommendation for biopsy, fine needle aspiration 
(FNA), or surgery were also considered positive or 3 (probably benign finding) with a 
recommendation for biopsy, fine needle aspiration (FNA), or surgery were also considered 
positive. A negative screening mammogram is defined as a screening mammogram with a BI-
RADS assessment category of 1, 2, or 3 with no recommendation for biopsy, FNA, or surgery.  
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CBCS-CMR Linkage 
 All cases and controls from Phases 1, 2 and 3 of CBCS (N=7331) were matched to all 
women in CMR from 1994-2014 inclusive (N=657,060) using probabilistic linkage. The 
following identifiers were used: last four digits of social security number (SSN), first name, last 
name, middle initial, date of birth, and address.  Because some women in CBCS Phase 3 did not 
consent to use of SSNs, Phase 3 of CBCS was linked separately for those with and those without 
SSN.  
 Matches (women that were in both CBCS and CMR) were determined using thresholds 
set based on linking probabilities of the identifiers chosen. The final linked dataset included 
2,614 women (871 controls and 1,743 cases of DCIS or invasive breast cancer). The sensitivity 
of linkage (100%) was the same for women linked with SSN information and those linked 
without, but specificity was higher (97.1% vs. 95.2%) for those with SSN information. Linkage 
was performed by the Integrated Cancer and Information Surveillance System (ICISS) at the 
University of North Carolina219. Consistent with screening patterns in the general population, 
CBCS women with records in the CMR were more likely to be cancer cases, older, post-
menopausal, and have used hormone replacement therapy.  
Eligibility criteria 
 The eligibility criteria applied in this study are shown in Figure 4.1. As a secondary 
quality control measure for the linkage, information from one commonly collected variable 
between the two data sets, date of diagnosis, was compared. Both CBCS and CMR collected data 
for this variable from the NC Central Cancer Registry; date of diagnosis should therefore be the 
same if the match from the linkage was correct. There were 15 of 1512 (0.1%) women where 
dates of diagnosis did not match. After manual review, it was determined that these women 
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represented false matches and these women were excluded from analysis. The final data set that 
was used for this study contained 1497 women. 43% of these women (N=644) had genomic data 
available. 
4.3.2 Defining interval vs. screen-detected cases 
 Invasive breast cancer cases were classified as interval or screen-detected based on 
the date of the most recent pre-diagnostic screening mammogram and the date of breast 
cancer diagnosis. Screening interval recommendations varied from 1-2 years28-31 during the 
study period (1993-2013). Mode of detection was defined using both a 12 and 24 month 
screening interval (Figure 4.2). For example, using the 24 month screening interval, if a 
positive screening mammogram was recorded in the 24 months before the diagnosis date, the 
cancer was classified as screen-detected.  If a negative screening mammogram was recorded 
in the 24 months before diagnosis, cancers were defined as interval cancers. The 24 month 
interval was chosen for the main analysis to reflect current screening recommendations and 
to enhance comparability with other studies47,72,77,91,138.  
 Of the 1,497 women with a primary invasive breast cancer in the CMR-CBCS data 
set, we identified 165 women who were screen-detected and 205 women who were interval-
detected within one year of a negative screening mammogram. Sensitivity analyses that 
decreased the screening interval to 12 months were also performed; using this interval, 161 
women were screen-detected and 107 women were interval-detected. Women who meet 
neither screen-detected nor interval-detected definitions were classified as “unknown”. 
Compared to screen-detected women, women with unknown mode of detection had less 
screening history in the linked dataset, were more likely to be <50 and premenopausal. 
Women with unknown mode of detection were excluded from all analyses. 
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4.3.3 Statistical analysis 
Logistic regression was used to calculate univariate odds ratios for associations for each 
of the demographic/patient variables (age, race, BMI, CBCS Phase, menopausal status, 
education, marital status, income, family history, hormone replacement therapy use, and 
mammographic density) with mode of detection, with screen-detected cancers being used as the 
referent group. Potential confounders were chosen a priori based on a review of the literature. 
Adjusted odds ratios were calculated for the association between clinical and molecular variables 
(tumor size, nodal status, cancer stage, ER, PR, and HER2 positivity, 3-marker subtype, 5-
marker subtype IHC p53, PAM50 subtype, genomic p53) and mode of detection; odds ratios 
were adjusted for demographic/personal variables found to be strongly associated in the previous 
analysis. All analyses were done in SAS version 9.3 (SAS Institute, Cary, NC). 
 Because mammographic density and race are potential effect measure modifiers of the 
relationship between patient and cancer characteristics and mode of detection, all analyses were 
repeated stratifying for mammographic density and race separately.  
4.4 Results 
The final analytic population contained 370 women. As described in Table 4.1, the 
majority of women were ≥ 50 (60%), White (53%), postmenopausal (64%), and had no first 
degree family history of breast cancer (79%). In addition, the majority of women were never 
users of hormone replacement therapy (68%) and had low (BI-RADS 1 or 2) breast density 
(55%). To assess patterns of mammography use, we evaluated mean number of mammography 
visits, mammographic exams (screening and diagnostic exams), and screening mammograms 
among all participants with at least one screening mammogram recorded during a prediagnostic 
screening interval (defined as more than two years before diagnosis, Table 4.1). Of 
57 
 
demographic/personal factors assessed, younger age (<50 years old, OR=1.44; 95% C.I.: 0.95, 
2.20), postmenopausal status (OR= 1.14; 95% C.I.: 0.94, 1.75), and high mammographic density 
(OR=2.02; 95% C.I.: 1.29, 3.16) were associated with interval detection (Table 4.2). 
Table 4.3 shows associations between interval-detected vs. screen-detected cancers and 
clinical characteristics. Interval cancers were associated with aggressiveness as measured by 
tumor size, stage, and nodal status.  Interval cancers were also more commonly hormone 
receptor negative, but these results were not significant, nor was an association with p53 status. 
However, interval cancers were statistically significantly associated with triple negative status 
(OR= 2.45; 95% C.I: 1.10, 5.47) and with basal-like cancer (OR=2.06; 95% C.I: 1.07, 3.95). 
Associations between mode of detection and molecular variables (ER, PR, HER2, triple 
negative, basal-subtype) were unchanged after adjusting for tumor size, stage, and nodal status.  
Interval cancers were strongly associated with genomic markers (Table 4.4), including 
PAM50 non-Luminal A subtype (OR=2.94; 95% C.I.: 1.52, 5.71) and PAM50 basal-like subtype 
(OR=2.68; 95% C.I.: 1.21, 5.94). Mean ROR-PT score was significantly higher in interval than 
screen-detected cancers (mean =41.0 vs. 26.0; p <0.001).  As shown in Figure 4.3, the kernel 
density distribution is shifted toward higher risk tumors among interval cancers and a higher 
proportion of ROR-PT high risk tumors, (24/105, 23%) were detected among interval-detected 
cancers (vs. 3/71, 4% among screen-detected). Associations between interval detection and 
tumor characteristics were not markedly changed when stratified by density (Table 4.3), race 
(Table 4.5), or by screening interval (Table 4.6).  
4.5 Discussion 
Identification of the predictors and characteristics of interval cancers contributes to our 
knowledge of the risks and benefits of mammography. We found that standard clinical prognosis 
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features are associated with interval cancers, and that genomic tests indicative of poor prognosis 
are more common among interval cancers.  Previous literature has shown that interval cancers 
tend to have negative prognostic characteristics 8,12,13,16,43,44, however we found associations to be 
weaker than reported previously for ER- or PR-12,44, triple negative8,43,44, and p53 mutant44.  With 
the exception of triple negative subtype, none of these were significantly associated with interval 
detection.  
While multi-gene classification methods have become more prominent clinically, 
genomic characteristics of interval cancers are not well studied. The only study that has reported 
associations between PAM50 results and mode of detection was based within a clinical cancer 
sequencing study in Sweden with 173 patients. That study had similar findings, showing that 
interval cancer was associated with basal-like subtype19.  Higher ROR-PT among interval 
cancers has not been assessed previously. It is striking that only 4% of screen-detected cancers 
had high ROR-PT, in parallel with high frequency of Luminal A subtype (71%).  
While our findings strongly support biologic determinants of interval cancers, masking 
bias may nonetheless contribute to interval cancer rates.  Multiple studies have shown high 
mammographic density to be associated with interval cancers45-47, including our own findings 
herein. However, it is difficult to disentangle tumor biology and mammographic density because 
younger women have both higher density and more aggressive tumor characteristics48,49. We 
were unable to consider the independent contributions of age, race, and mammographic density 
due to sample size.  
Some limitations of the study should be noted. CMR does not include all breast imaging 
facilities in North Carolina, so only ~30% of women enrolled in CBCS were linked to CMR. 
Furthermore, CBCS oversampled younger and African American women, and therefore the 
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proportion of screen and interval detected cases may vary as a function of the demographic and 
selection characteristics of CBCS48.  Therefore our study is not designed to estimate the 
proportion of screen and interval-detected cases in the general population. Notably, among 
screened women, we classified 45% of invasive cases as screen-detected. Previous studies based 
on CMR have reported higher proportions of screen detected cases (e.g. Henderson et al. 
reported 80% of cases were screen detected using a 1 year-interval14; Hofvind et al. reported 
60% of cases were screen detected given the 24-month definitions used herein11). We were 
unable to retrospectively review mammographic images to confirm which interval cases arose 
from false negatives, but we minimized misclassification within screen and interval-detected 
groups by classifying women with missing screening data as ‘unknown’. We note that the 
unknown category likely includes true screen- and interval-detected cases along with true 
clinically detected cases. Despite these limitations, this study does provide novel data on 
genomic characteristics in a racially diverse population.  
The goal of mammography is to find aggressive cancers at an earlier stage to increase 
survivorship and reduce mortality. Our research shows that a high proportion of interval cancers 
are associated with aggressive biology. Our work also suggests that genomic tests may be useful 
in distinguishing indolent vs. aggressive screen-detected cancers, given the high prevalence of 
low-risk tumors among screen-detected cases. If confirmed, these findings indicate that 
continued evaluation of genomic tools in combination with mammography could help to increase 
the benefit and reduce negative consequences of screening. 
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Figure 4.1 Flowchart of eligibility criteria. 
 
 
 
 
 
All linked 
(CBCS-CMR)
(N=2614)
Cases 
(N=1743)
Invasive Cases 
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(N=644)
Excluded: Incorrect 
match based on 
diagnosis date (N=15)
Excluded: 
DCIS 
(N=231)
Excluded: 
Controls 
(N=871)
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Figure 4.2 Mode of detection categorization, using 12 or 24 month screening interval. 
 
1 Women who had unknown mode of detection were excluded from this study.  
 
 
Eligible for 
analysis
(N=1497)
Screening mammogram 
within 12 or 24 months 
of diagnosis
Positive
Screen-detected
12 month: N=161 (60%)
24 month: N=165 (45%)
Negative
Interval-detected
12 month: N=107 (40%)
24 month: N=205 (55%)
No screening 
mammogram within 12 
or 24 months of 
diagnosis
Unknown1
Table 4.1 Characteristics of full analytic set and pre-diagnosis mammography use for women with mammography recorded in CMR 
>2 years before diagnosis of invasive breast cancer (N=209). 
  Full 
analysis 
data set 
(N=370) 
N (%) 
 Women with 
mammography 
recorded > 2 
years before 
diagnosis 
(N=209) 
N (%) 
Mean 
number 
of visits 
(SD) 
p Mean 
number of 
exams (SD) 
p Mean number 
of screening 
mammograms 
(SD) 
p 
Age         
 <50 148 (40) 70 (33) 4.7 (4.0)  3.6 (3.1)  2.9 (2.7)  
≥50 222 (60) 139 (66) 7.1 (5.2) 0.02 5.8 (4.0) <0.0001 5.3 (3.8) <0.0001 
Race         
White 197 (53) 115 (55) 6.5 (5.3)  5.2 (4.0)  4.5 (3.8)  
African 
American 
173 (47) 94 (45) 6.1 (4.6) 0.5 4.8 (3.7) 0.5 4.4 (3.4) 0.8 
Menopausal 
status 
        
Pre 134 (36) 62 (30) 4.7 (3.7)  3.7 (3.0)  3.1 (2.8)  
Post 236 (64) 147 (70) 7.0 (5.3) 0.003 5.6 (4.1) 0.001 5.1 (3.8) <0.0001 
Education         
        ≤ High 
school 
194 (52) 112 (54) 6.7 (5.4)  5.4 (4.1)  4.9 (3.9)  
       > High school 176 (48) 97 (46) 5.8 (4.5) 0.2 4.6 (3.6) 0.1 4.0 (3.3) 0.1 
Income         
                < 30,000 137 (40) 81 (42) 6.9 (5.4)  5.6 (4.3)  5.0 (3.7)  
                ≥ 30,000 211 (61) 114 (58) 5.9 (4.6) 0.2 4.6 (3.6) 0.1 4.1 (3.6) 0.1 
Missing 22 14       
Family historya         
No 282 (79) 156 (77) 6.3 (4.9)  5.0 (3.8)  4.3 (3.5)  
Yes 76 (21) 47 (23) 6.6 (5.5) 0.7 5.0 (4.2) 1.0 4.9 (4.0) 0.4 
6
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Missing 12  6       
Marital status         
Married 217 (59) 131 (63) 6.2 (5.2)  4.9 (3.9)  4.3 (3.5)  
Single 42 (11) 25 (12) 6.4 (5.0) 0.8 4.9 (3.7) 1.0 5.1 (4.6) 0.4 
Widowed/ 
divorced 
111 (30) 53 (25) 6.7 (4.4) 0.5 5.5 (3.9) 1.0 4.7 (3.4) 0.4 
HRT use         
Never 244 (68) 126 (63) 5.8 (4.4)  4.7 (3.6)  3.9 (3.4)  
Current/ former 117 (32) 75 (37) 6.6 (5.1) 0.2 5.2 (3.8) 0.3 5.2 (3.9) 0.03 
Missing 9 8       
BI-RADS 
mammographic 
breast densityb 
        
Non-dense 178 (55) 109 (64) 6.2 (5.4)  5.1 (4.2)  4.5 (3.9)  
Dense 145 (45) 61 (36) 5.7 (4.4) 0.5 4.5 (3.4) 0.4 3.8 (2.9) 0.2 
Missing 47 39       
Mode of 
detection 
        
Screen 165 (45) 85 (41) 6.0 (4.8)  4.9 (3.7)  4.0 (3.3)  
Interval 205 (55) 124 (59) 6.5 (5.1) 0.5 5.1 (4.0) 0.7 4.8 (3.9) 0.1 
aFirst degree family history of breast cancer. 
bNon-dense= BI-RADS categories 1&2; Dense= BI-RADS categories 3&4. 
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Table 4.2 Univariate odds ratios (OR) and 95% confidence intervals (95% CI) for 
demographic/personal characteristics comparing interval-detected vs. screen-detected cancers. 
  Screen-detected 
(N=165) 
Interval 
(N=205) 
OR (95% CI) 
 N (%) N (%)  
Age    
≥50 107 (65) 115 (56) 1.00 
 <50 58 (35) 90 (44) 1.44 (0.95, 2.20) 
Race    
White 85 (52) 112 (55) 1.00 
Black 80 (48) 93 (45) 0.88 (0.59, 1.33) 
BMI    
Underweight 0 3 (1)  
Normal 37 (23) 53 (26) 1.00 
Overweight 127 (77) 147 (72) 0.81 (0.50, 1.31) 
Missing 1 2  
 CBCS Phase    
Phase 1&2 73 (44) 72 (35) 1.00 
Phase 3 92 (56) 133 (65) 1.01 (0.62, 1.65) 
Menopausal status    
Post 108 (65) 128 (62) 1.00 
Pre 57 (35) 77 (38) 1.14 (0.94, 1.75) 
Education    
>  High school 75 (45) 101 (49) 1.00 
High school or less 90 (55) 104 (51) 0.86 (0.57, 1.29) 
Marital status    
Married 94 (57) 123 (8) 1.00 
Single 18 (11) 24 (12) 1.02 (0.52, 1.99) 
Divorced 53(32) 58 (29) 0.84 (0.53, 1.32) 
Family History a    
No 124 (79) 158 (79) 1.00 
Yes 33 (21) 43 (21) 1.02 (0.66, 1.73) 
Missing 8 4  
HRT use    
Never 107 (67) 137 (68) 1.00 
Current/ Former 53 (33) 64 (32) 0.94 (0.61, 1.47) 
Missing 5 4  
65 
 
BI-RADS 
mammographic breast 
density b 
   
Non-dense 85 (54) 77 (38) 1.00 
Dense 73 (46) 124 (62) 2.02 (1.29, 3.16) 
Missing 7 4  
a First degree female family history. 
b Low density= BI-RADS categories 1&2; High density= BI-RADS categories 3&4. 
 
 
Table 4.3. Interval vs. Screen-detected cancers: Associations with clinical characteristics stratified by mammographic density. 
 Overall Non-dense Dense 
  
SDC 
(N=165) 
Interval 
(N=205) 
Adjusted OR 
(95% CI)a 
SDC 
(N=93) 
Interval 
(N=85) 
Adjusted OR 
(95% CI) a 
SDC 
(N=51) 
Interval 
(N=94) 
Adjusted 
OR (95% 
CI) a 
 N (%) N (%)  N (%) N (%)  N (%) N (%)  
Age          
≥50 107 (65) 115 (56) 1.0 65 (70) 52 (61) 1.00 30 (59) 46 (49) 1.00 
 <50 
58 (35) 90 (44) 1.44 (0.95, 2.20) 28 (30) 33 (39) 1.47 (0.79, 2.74) 21 (41) 48 (51) 
1.49 (0.75, 
2.97) 
Tumor size          
≤ 2 cm 115 (70) 103 (52) 1.0 69 (78) 42 (51) 1.00 33 (66) 44 (49) 1.00 
> 2 cm 
44 (27) 94 (46) 2.33 (1.48, 3.65) 20 (22) 41 (49) 3.22 (1.66, 6.26) 17 (34) 45 (51) 
2.00 (0.97, 
4.12) 
Missing 6 8  4 2  1 5  
Nodal status          
Negative 123 (75) 127 (62)  68 (74) 51 (60) 1.00 38 (75) 61 (66) 1.00 
Positive 
41 (25) 77 (38) 1.78 (1.13, 2.81) 24 (26) 34 (40) 1.78 (0.94, 3.39) 13 (25) 32 (34) 
1.58 (0.73, 
3.42) 
Missing 1 1  1 0  0 1  
Stage          
I/ II 151 (94) 172 (86)  85 (94) 69 (83) 1.00 46 (92) 81 (89) 1.00 
III/ IV 
9 (6) 28 (14) 3.22 (1.43, 7.25) 5 (6) 14 (17) 3.21 (1.09, 9.44) 4 (8) 10 (11) 
1.38 (0.40, 
4.74) 
Missing 5 5  3 2  1 3  
ER          
Positive 112 (71) 124 (65) 1.0 62 (70)  1.00 35 (70) 58 (67) 1.00 
Negative 
46 (29) 66 (35) 1.25 (0.79, 1.98) 26 (30) 31 (39) 1.44 (0.75, 2.77) 15 (30) 29 (33) 
1.15 (0.54, 
2.45) 
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Missing 7 17  5 6  1 7  
PR          
Positive 94 (61) 96 (50) 1.0 48 (57) 35 (45) 1.00 33 (66) 50 (56) 1.00 
Negative 
60 (39) 96 (50) 1.53 (0.99, 2.37) 36 (43) 43 (55) 1.57 (0.84, 2.95) 17 (34) 39 (44) 
1.58 (0.76, 
3.28) 
Missing 11 13  9 7  1 5  
HER2          
Positive 20 (14) 23 (12) 1.0 11 (13) 6 (8) 1.00 6 (13) 11 (13) 1.00 
Negative 
127 (86) 162 (88) 1.24 (0.64, 2.38) 72 (87) 69 (92) 1.84 (0.63, 5.33) 39 (87) 75 (87) 
1.32 (0.43, 
4.00) 
Missing 18 20  10 10  6 8  
p53 IHC          
Wild 
type 
75 (71) 78 (67) 1.0 43 (72) 31 (66) 1.00 23 (70) 38 (68) 1.00 
Mutant 
30 (29) 39 (33) 1.23 (0.69, 2.18) 17 (28) 16 (34) 1.28 (0.55, 2.95) 10 (30) 18 (32) 
1.08 (0.41, 
2.81) 
Missing 60 88  33 38  18 38  
a All odds ratios, except those for age, are adjusted for age and menopausal status 
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Table 4.4 Odds ratios for molecular characteristics for linked invasive cases. 
 Screen-
detected 
(N=165) 
Interval 
(N=205) 
Adjusted OR (95% 
CI)a 
 N (%) N (%)  
3-marker subtype    
Luminal A 99 (68) 102 (55) 1.00 
Luminal B 14 (10) 16 (9) 0.95 (0.43, 2.08) 
HER2 6 (4) 7 (4) 1.12 (0.36, 3.45) 
Triple negative 26 (18) 60 (32) 2.45 (1.10, 5.47) 
Missing 20 20  
5-marker subtype    
Luminal A 67 (64) 64 (47) 1.00 
Luminal B 12 (12) 30 (22) 2.45 (1.14, 5.25) 
HER2 6 (6) 4 (3) NRb 
Basal 19 (18) 38 (28) 2.06 (1.07, 3.95) 
Missing 61 69  
PAM50    
Luminal A 51 (71) 46 (46) 1.00 
Luminal B 4 (6) 18 (18) 5.29 (1.63, 17.10) 
HER2 5 (7) 8 (8) 1.82 (0.54, 6.15) 
Basal 12 (17) 29 (29) 2.68 (1.21, 5.94) 
Missing 93 104  
PAM50    
Luminal A 51 (71) 46 (46) 1.00 
Non-Luminal A 21 (29) 55 (54) 2.94 (1.52, 5.71) 
Missing 93 104  
p53    
Wild type 42 (55) 55 (52) 1.00 
Mutant 34 (45) 51 (48) 1.13 (0.63, 2.05) 
Missing 89 99  
ROR-PT    
Low/ Medium 68 (96) 81 (77) NRb 
High 3 (4) 24 (23) NRb 
Missing 94 100  
a All odds ratios are adjusted for age and menopausal status. 
b Odd ratios are not reported where cell size < 5 observations. 
 
 
 
Table 4.5 Interval vs. Screen-detected cancers: Associations with clinical characteristics stratified by race. 
 Black White 
  SDC 
(N=80) 
Interval 
(N=93) 
Adjusted OR (95% CI) a 
SDC 
(N=85) 
Interval 
(N=112) 
Adjusted OR (95% CI) a 
 N (%) N (%)  N (%) N (%)  
Age       
≥50 57 (71) 52 (56) 1.00 50 (59) 63 (56) 1.00 
 <50 23 (29) 41 (44) 1.95 (1.04, 3.68) 35 (41) 49 (44) 1.11 (0.63, 1.97) 
Tumor size       
≤ 2 cm 53 (71) 40 (44) 1.00 62 (74) 63 (59) 1.00 
> 2 cm 22 (29) 50 (56) 2.79 (1.44, 5.40) 22 (26) 44 (41) 1.95 (1.04, 3.65) 
Missing 5 3  1 5  
Nodal status       
Negative 20 (25) 35 (38) 1.00 21 (25) 42 (38) 1.00 
Positive 59 (75) 58 (62) 1.83 (0.93, 3.59) 64 (75) 69 (62) 1.79 (0.95, 3.36) 
Missing 1 0  0 (0) 1  
Stage       
I/ II 73 (96) 78 (85) 1.00 78 (93) 94 (87) 1.00 
III/ IV 3 (4) 14 (15) 4.39 (1.2, 16.07) 6 (7) 14 (13) 1.84 (0.67, 5.11) 
Missing 4 1  1 4  
ER       
Positive 49 (65) 50 (57) 1.00 63 (76) 74 (73) 1.00 
Negative 26 (35) 38 (43) 1.35 (0.71, 2.57) 20 (24) 28 (27) 1.13 (0.57, 2.21) 
Missing 4 3  2 (2) 10  
PR       
Positive 44 (59) 33 (38) 1.00 50 (63) 63 (59) 1.00 
Negative 30 (41) 53 (62)  2.29 (1.21, 4.36) 30 (38) 43 (41) 1.06 (0.58, 1.94) 
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Missing 6 7  5 (6) 6  
HER2       
Positive 9 (13) 15 (18) 1.00 11 (14) 8 (8) 1.00 
Negative 61 (87) 70 (82) 0.77 (0.31, 1.92) 66 (86) 92 (92) 2.26 (0.83, 6.13) 
Missing 10 8  8 12  
3-marker 
subtype 
      
Luminal A 45 (65) 38 (45) 1.00 54 (71) 64 (64) 1.00 
Luminal B 5 (7) 11 (13) 2.14 (0.66, 6.92) 9 (12) 5 (5) 0.35 (0.10, 1.18) 
HER2 4 (6) 4 (5) NRb 2 (3) 3 (3) NRb 
Triple 
negative 
15 (22) 32 (24) 2.28 (1.06, 4.91) 11 (14) 28 (28) 1.89 (0.84, 4.25) 
Missing 11 8  9 12  
5-marker 
Subtype 
      
Luminal A 34 (63) 19 (30) 1.00 33 (66) 45 (62) 1.00 
Luminal B 5 (7) 18 (29) 8.10 (2.25, 27.93) 8 (16) 12 (16) 0.95 (0.34, 2.70) 
HER2 4 (9) 3 (5) NRb 1 (2) 1 (1) NRb 
Basal 11 (20) 23 (37) 3.70 (1.45, 9.47) 8 (16) 15 (21) 1.34 (0.50, 3.60) 
Missing 26 30  35 39  
p53 IHC       
Wild type 39 (70) 35 (67) 1.00 36 (73) 43 (66) 1.00 
Mutant 17 (30) 17 (33) 1.08 (0.47, 2.46) 13 (27) 22 (34) 1.31 (0.57, 3.03) 
Missing 24 41  36 47  
aAll odds ratios, except those for age, are adjusted for age and menopausal status. 
b Odd ratios are not reported where cell size < 5 observations. 
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Table 4.6 Summary table comparing odds ratios of interest (Interval vs. screen-detected 
cancers). 
 1 year intervala 
OR (95% CI) 
2 year intervalb 
OR (95% CI) 
<50 vs. ≥50 1.84 (1.12, 3.03) 1.44 (0.95, 2.20) 
Black vs. white 0.78 (0.48, 1.27) 0.88 (0.59, 1.33) 
High vs. low density 2.34 (1.38, 4.00) 2.02 (1.29, 3.16) 
≤ 2 cm vs.  < 2 cm 3.40 (2.00, 5.79) 2.33 (1.48, 3.65) 
ER- vs. ER+ 1.44 (0.83, 2.50) 1.25 (0.79, 1.98) 
PR- vs. PR+ 1.53 (0.91, 2.61) 1.53 (0.99, 2.37) 
Triple negative vs. 
Luminal A 
2.50 (1.33, 4.71) 
2.45 (1.10, 5.47) 
Basal vs. Luminal A 2.24 (1.05, 4.76) 2.06 (1.07, 3.95) 
a Mode of detection constructed using 1 year interval: interval-detected (N=107), screen-detected 
(N=161). 
b Mode of detection constructed using 2 year interval: interval-detected (N=205), screen-detected 
(N=165). 
Figure 4.3 Kernel density distribution of PAM50 risk of recurrence (ROR) score for interval- and screen-detected cancers. ROR 
distributions of screen-detected and interval-detected cancers are blue and red, respectively. The area shaded under the curve 
represents the proportion of cancers that have high risk of recurrence score. Of 105 interval-detected cancers that had genomic data 
available, 24 cancers (23%) had high ROR score. Of 71 screen-detected cancers that had genomic data available, 3 cancers (4%) had 
high ROR score. 
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CHAPTER 5: MAMMOGRAPHIC IMAGING FEATURES AND MOLECULAR AND 
GENOMIC BREAST CANCER SUBTYPE 
 
5.1 Overview 
Introduction:  Breast cancers detected by mammography may appear as masses, with 
calcifications, or with other imaging features. Patterns of imaging features by breast cancer 
subtype are not well-characterized. We examined the association between age, race, and 
molecular and genomic subtypes of breast cancer and distinct mammographic features. 
Methods: We identified 412 women diagnosed with a primary invasive breast cancer 
from 1993-2013 and who had imaging features recorded on a mammogram within two years of 
diagnosis by linking the Carolina Breast Cancer Study and the Carolina Mammography Registry. 
Linear regression was used to estimate prevalence differences (PD) as measures of associations 
between imaging features (masses and calcifications) and patient, immunohistochemical, and 
genomic characteristics.  
Results: Overall, masses and calcifications were reported in 49% and 20% of cases, 
respectively. Both young (<50 years) and African-American women showed higher relative 
frequency of masses and lower relative frequency of calcifications compared to older (≥ 50) and 
White women. Masses were less frequent among interval-detected vs. screen-detected women 
(33% vs. 46%, p=0.04). Relative to Luminal A breast cancers (42% presenting as masses), 
PAM50 Basal-like and HER2-enriched subtypes were more likely to present as masses (59% and 
72%, respectively). High risk of recurrence (ROR-PT) score was also associated with presenting 
as only a mass (50% vs. 28% among low  ROR-PT tumors, p=0.03).  Conversely, few Basal-like 
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and ROR-PT high cancers presented with calcifications (n=4/49 basal-like and n=3/30 ROR-PT 
high). 
Conclusions: Distinct molecular and genomic subtypes of breast cancer present with 
distinct mammographic features. Improving detection of aggressive subtypes may depend upon 
ability to accurately and sensitively detect masses. 
5.2 Introduction 
Mammography is the most common breast cancer screening method, and consists of a 
low dose x-ray image of the breast. The presence of mammographic imaging features is used in 
the detection and diagnosis of breast cancer, with masses being most common, followed by 
calcifications, architectural distortion, and asymmetry140,141. The likelihood of detecting a tumor 
using screening mammography may vary as a function of the imaging characteristics of the 
breast cancer155,156.  If breast cancer subtype is associated with specific imaging features, 
screening efficacy may vary by subtype accordingly91,92,222. 
In this study, we describe associations between imaging features and molecular and 
genomic breast cancer subtypes as a step towards understanding the relationship between 
subtype, imaging features, and mammographic detection. Specifically, we evaluated genomic 
subtypes (Basal-like, Luminal A, Luminal B, HER2-enriched) using RNA expression 
patterns92,104,111-113 along with the  research version of the clinically-utilized PAM50 risk of 
recurrence (ROR-PT)127, a genomic risk score that incorporates tumor subtype, expression-based 
measures of proliferation, and clinical tumor size.  There have been a small number of published 
studies that have examined the association between breast cancer subtype and imaging 
features141,142,153 but no studies have examined genomic tests in association with mammographic 
features.  
75 
 
5.3 Methods 
5.3.1 Data Sources 
Carolina Breast Cancer Study 
The Carolina Breast Cancer Study (CBCS) is a population-based study designed to 
identify both genetic and environmental risk factors for breast cancer among North Carolina 
women190. The current analysis uses data from all three study phases of CBCS (Phase 1, 1993-
1996; Phase 2, 1996-2001; and Phase 3, 2008-2013). Randomized recruitment was used to 
oversample both African American and younger cases (under age 50)114,192 in all phases. The 
first two phases of CBCS recruited both cases and controls from 24 counties of eastern and 
central NC190. Cases were women aged 20 to 74 diagnosed with a primary invasive breast cancer 
between May 1, 1993 and December 31, 2000 and identified through rapid case ascertainment 
from the North Carolina Central Cancer Registry. Cases of in situ cancer were also enrolled in 
Phase 2. A total of 1803 invasive breast cancer cases were enrolled in Phases 1&2. Phase 3 of 
CBCS recruited invasive cases only (N=3000) from 44 counties in NC. 
CBCS Variables 
Women in the CBCS were interviewed at baseline by a nurse, at which point they also 
provided written informed consent for medical record requests. All demographic (age at 
diagnosis and race), clinical (tumor size and stage), and molecular data used in this study came 
from CBCS. 
The following IHC markers were used to distinguish intrinsic subtype: ER, PR HER2, 
human epidermal growth factor-1 (EGFR), and cytokeratin 5/6 (CK5/6. For Phases 1&2 of the 
CBCS, previously described assays were used to stain and quantify these IHC markers111,204,205. 
ER and PR status were determined from medical records for the 80% of women who had these 
data available from medical records204; for the remaining cases with paraffin-embedded tissue 
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available, IHC analysis was performed at the University of North Carolina Translational 
Pathology Laboratory (TPL). Positivity for ER and PR status was defined as having more than 
5% of cells showing nuclei-specific staining111. Tumors with HER2 staining in more than 10% of 
cells were considered HER2 positive205.  Positivity of EGFR was defined as any staining and 
positivity for CK 5/6 was defined as any cytoplasmic and/or membranous staining. Previously 
identified IHC definitions for intrinsic subtypes were used111,206. Methods to distinguish intrinsic 
subtypes in CBCS Phase 3 were described in detail by Allot et al.128. Briefly, tissue microarrays 
(TMAs) were constructed and stained by the TPL and were digitally imaged using the Aperio 
ScanScope XT (Aperio Technologies, Vista CA). Automated digital image analysis was 
performed to quantify IHC staining using a Genie classifier and the Nuclear V9 algorithm 
(Aperio Technologies, Vista CA), for ER and PR and a Genie classifier and Membrane V9 
algorithm for HER2. 
 PAM50 gene expression subtyping was performed on a subset (n=2007) of samples 
with available formalin-fixed paraffin embedded cores or unstained slides from CBCS 
Phases 1-3 as described previously128. RNA was isolated using the RNeasy FFPE Kit 
(Qiagen) and Nanostring analyses were performed in the Rapid Adoption Molecular 
laboratory and the Translational Genomics laboratory at UNC. Tumors were classified as 
Luminal A, Luminal B, HER2-enriched, Basal-like, and normal-like using the PAM50 
predictor127. A subset of the PAM50 genes were also used to construct the risk of recurrence 
score, taking into account proliferation and tumor size (ROR-PT)208. ROR-PT is the research 
correlate to the clinically used Prosigna assay (NanoString Technologies Inc., Seattle, WA, 
USA), which has been clinically validated209. ROR-PT is a continuous score, but can be 
categorized (Low/Medium/High) using published protocols127. 
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Carolina Mammography Registry 
The Carolina Mammography Registry (CMR)193 is a large community-based 
mammography registry that has studied the performance and outcomes of mammography in 
North Carolina since 1994 and participates in the Breast Cancer Surveillance Consortium 
(BCSC)216. CMR collects data from breast imaging facilities across North Carolina. Data from 
patients and radiologists include patient demographics, prior screening history, breast cancer risk 
factors including family history of breast cancer, radiologist-reported breast density using Breast 
Imaging Reporting and Data System (BI-RADS) classifications, reason for the visit, screening 
and diagnostic procedures performed, and radiologists’ interpretation of the examination using 
the American College of Radiology BI-RADS assessment categories and the recommended 
follow-up.  
CMR Variables 
All mammography data used in this analysis, including mammographic density, type of 
examination, screening dates, and screening outcomes came from the CMR. In the CMR, 
mammographic density is recorded at each mammogram by the interpreting radiologist using BI-
RADS classifications. For all analyses, mammographic density was categorized as non-dense 
(BI-RADS 1 and 2) or dense (BI-RADS 3 and 4)217.   
Mammogram findings were reported by the radiologists using BI-RADS assessment 
categories202. Screening mammograms and results were defined using BCSC definitions218. A 
mammogram was considered to be screening if: the woman was 18 or older, had no breast 
implants or prior mastectomy, no history of breast cancer, the indication for the examination was 
routine screening, it was the first examination sequence of the day, bilateral screening views 
were done, there was no imaging in the previous 9 months, and the overall assessment code was 
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not BI-RADS 6. A positive screening mammogram is defined as a screening mammogram with a 
BI-RADS assessment code of 4 (suspicious abnormality) or 5 (highly suggestive of malignancy). 
Screening mammograms with a BI-RADS assessment code of 0 (incomplete) or 3 (probably 
benign finding) with a recommendation for biopsy, fine needle aspiration (FNA), or surgery 
were also considered positive. A negative screening mammogram was defined as a screening 
mammogram with a BI-RADS assessment category of 1, 2, or 3 with no recommendation for 
biopsy, FNA, or surgery.  
CBCS-CMR Linkage 
All cases and controls from Phases 1, 2 and 3 of CBCS (N=7331) were matched to all 
women in CMR from 1994-2014 inclusive (N=657,060) using probabilistic linkage. The 
following identifiers were used to match records: last four digits of social security number 
(SSN), first name, last name, middle initial, date of birth, and address.  Because some women in 
CBCS Phase 3 did not consent to use of SSNs, Phase 3 of CBCS was linked separately for those 
with and those without SSN.  
 Matches (women that were in both CBCS and CMR) were determined using thresholds 
set on linking probabilities of the identifiers chosen. The final linked dataset included 2,614 
women (871 controls and 1,743 cases of DCIS or invasive breast cancer). The sensitivity of 
linkage (100%) was the same for women linked using SSN information and those linked without, 
but linkage specificity was higher (97.1% vs. 95.2%) for those with SSN. Linkage was 
performed by the  Cancer Information and Population Health Resource (CIPHR) at the 
University of North Carolina219. Consistent with screening patterns in the general population, 
CBCS women with records in the CMR were more likely to be cancer cases, older, post-
menopausal, and have used hormone replacement therapy.  
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Eligibility Criteria 
 The eligibility criteria applied in this study are shown in Figure 5.1. As a secondary 
quality control measure for the linkage, information from one commonly collected variable 
between the two data sets, date of diagnosis, was compared. Both CBCS and CMR collected data 
for this variable from the NC Central Cancer Registry; date of diagnosis should therefore be the 
same if the match from the linkage was correct. There were 15 of 1512 (0.1%) women where 
dates of diagnosis did not match. After manual review, it was determined that these women 
represented false matches and these women were excluded from analysis. The linked dataset 
contained 1497 women. Of these women, 412 had imaging feature data available and were 
included in this study. 
5.3.2 Defining Interval vs. Screen-detected Cases 
 Invasive breast cancer cases were classified as interval- or screen-detected based on 
the result of the most recent pre-diagnostic screening mammogram and the date of breast 
cancer diagnosis. Screening interval recommendations varied from 1-2 years28-31 during the 
study period (1993-2013). Mode of detection was defined using a 24month screening interval 
(Figure 1). For example, using the 24-month screening interval, if a positive screening 
mammogram was recorded in the 24 months before the diagnosis date, the cancer was 
classified as screen-detected.  If a negative screening mammogram was recorded in the 24 
months before diagnosis, the cancer was classified as interval-detected.  Women who met 
neither screen-detected nor interval-detected definitions, including those who did not have a 
screening mammogram recorded in the 24 months prior to diagnosis, were classified as 
“missing”. 
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5.3.2 Defining absence/ presence of imaging features 
The indication for the study (screening/diagnostic/ follow-up), breast composition, 
important findings (imaging features), and final assessment (negative, benign, etc.) are recorded 
for each imaging exam. BI-RADS classifications, which can be used to predict malignancy211-213, 
for each imaging feature are noted by the radiologist for each imaging exam performed. Imaging 
features used in this analysis were mass and calcifications. Architectural distortion and 
asymmetry were not used due to low prevalence in our study sample. All data on these features 
were extracted from the most recent diagnostic exam (recorded within two years before to 30 
days after diagnosis) when possible. Data from the most recent (within two years before 
diagnosis) screening mammogram was used for women who did not have diagnostic exam data 
available. Due to power considerations, imaging features were categorized dichotomously. A 
feature was considered “absent” when BI-RADS=1; a feature was categorized as “present” when 
BI-RADS=2, 3, 4, or 5. The imaging feature variables used in analysis were any mass (mass ± 
calcifications), any calcifications (calcification ± mass), and mass only (mass without 
calcifications). Presence of any mass was the most common (49%), followed by mass only 
(42%), and any calcifications (20%). 
5.3.3 Statistical analysis 
Chi-square tests were used to study differences in mammographic feature presentation by 
patient, clinical, molecular, and genomic factors. Prevalence differences and their associated 
95% confidence intervals were calculated using generalized linear models. Differences in 
frequencies of imaging features were observed by CBCS phase of study; therefore, all prevalence 
difference analyses were controlled for CBCS phase.  A sensitivity analysis using only data from 
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diagnostic exams was also performed; results were similar to what is presented here. All analyses 
were done in SAS version 9.3 (SAS Institute, Cary, NC). 
5.4 Results 
 Table 5.1 describes prevalence differences between imaging features and demographic 
characteristics. Masses in the absence of calcifications were more common among women <50 
(50% vs. 35%, p=0.004). We also observed racial differences in prevalence of mammographic 
features. Calcifications were 9% less frequent among African-American vs. White women (25% 
vs. 16%, p=0.02). Conversely, masses were 18% (58% vs. 40%, p <0.001) more frequent and 
masses in the absence of calcifications were 20% more frequent (52% vs. 32%, p <0.001) in 
African-American compared to White women. We also found that tumor size was associated 
with imaging features; larger tumors (>2 cm) had higher frequency of masses (56% vs. 45%) and 
masses without calcifications (47% vs. 39%) relative to tumors ≤ 2 cm. Both masses (33% vs. 
46%, p=0.04) and masses without calcifications (28% vs. 40%, p=0.05) were less frequent 
among interval-detected vs. screen-detected cancers. No differences in frequency of 
mammographic features were seen by stage or mammographic density.  
 Table 5.2 shows associations between molecular and genomic characteristics and 
imaging features. We did not find statistically significant associations for any of the 
individual hormone receptors or for IHC intrinsic subtype, although we observed a trend of a 
higher prevalence of masses among ER- vs. ER+, PR- vs. PR+, and all non-Luminal A 
subtypes vs. Luminal A cancers. We found stronger associations when using PAM50 
genomic subtype, most notably with respect to cancers that presented as mass only. Basal-
like (53% vs. 33%, p=0.02) and HER2-enriched (66% vs. 33%, p=0.01) cancers more 
frequently presented with masses only compared to Luminal A cancers. There was a higher 
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prevalence masses without calcifications among women with high vs. low (50% vs. 28%, 
p=0.03) or medium vs. low (44% vs. 28%, p=0.04) ROR-PT score. In addition, only 3 
women with calcifications had high ROR-PT score. In an additional set of models, adjusted 
for age and race, associations between mammographic features and tumor molecular 
characteristics were no longer observed (Table 5.3). 
5.5 Discussion 
In the current study, we evaluated associations between molecular phenotypes and how 
cancers present mammographically. By identifying if specific subtypes present with features that 
may be difficult to detect, examining subtype-specific differences in mammographic features 
may contribute to our understanding of mammography efficacy. We observed a consistent 
pattern when studying IHC and genomic subtypes, with triple negative, HER2, and Basal-like 
cancers more commonly presenting as masses relative to Luminal cancer.  Younger (<50) and 
African-American women were also more likely to have their tumors detected as masses, in line 
with higher rates of aggressive cancers in these groups114. We extended previous insights on 
molecular associations to include genomic data for the first time and found that subtype 
associations with imaging features were slightly stronger when using PAM50 vs. IHC subtype. 
When considering the risk of recurrence score, both masses and masses without calcifications 
were associated with a high ROR-PT score.  Calcifications were rare in high risk genomic 
subtypes. 
The prevalence of imaging features in our study corresponds with what has been reported 
in other populations, with the majority of cancers detected with masses and a smaller proportion 
presenting with calcifications (20-27%)141,155. Likewise, our findings that aggressive features 
such as ER and PR negativity and HER2 positivity are associated with masses rather than 
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calcifications and are in accordance with previous studies141,153,154,225,226. Associations between 
imaging features and race are not well-studied. One other study has reported racial differences, 
also finding that prevalence of masses were higher among Black women141.   
 Our data are consistent with previous reports implying that calcifications are associated 
with smaller size.  We observed that smaller tumors (<2 cm) were more frequent in cases with 
calcifications. Previous literature suggests that the majority of breast cancers detected via 
calcifications are DCIS rather than invasive179,227.  Sensitivity of mammography to calcification 
detection has also led to concerns of overdetection. Our results are consistent with this, as we 
found that a small minority of tumors (10%) presenting with calcifications had high ROR-PT 
score, while a larger proportion of those presenting with masses (19%) had high ROR-PT. It is 
possible that combining information on imaging features with genomic testing, as a companion 
diagnostic, could help distinguish indolent and aggressive screen-detected cancers. Furthermore, 
use of imaging technology that is more sensitive to mass detection, such as tomosynthesis228,229, 
may lead to improved detection of aggressive cancers. 
Biological mechanisms explaining associations between mammographic features and 
breast cancer subtype have not yet been characterized. If the prevalence of specific 
mammographic features reflects the product of their incidence and duration, lower prevalence of 
calcifications may be expected for cancers with rapidly growing tumors, such as those that are 
the Basal-like subtype.  However, it is unknown whether all tumor subtypes have a state that is 
detectable via calcifications, or whether the unique biological characteristics of Basal-like breast 
cancers, for example, preclude a calcification state entirely.  The presence of a small number of 
Basal-like cases with calcifications in our study suggest that this subtype can present with 
calcifications. Identifying the mechanism of how imaging features such as calcifications and 
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masses develop can provide further insight into how aggressive cancers are able to avoid 
detection. 
 Limitations of this study include that data on the clinical relevance of our imaging 
features was limited for our study. That is, calcifications that were noted on a mammogram may 
not have been central to detection for a given case. We also lacked detailed information of 
mammographic features such as mass shape (irregular/ lobulated/ oval/ round), mass margins 
(noncircumscribed/ circumscribed), and calcification type (round/ amorphous/ fine linear), some 
of which have been shown to be associated with breast cancer subtype187,230,231. Heterogeneity 
within imaging feature groups may have attenuated some of our associations with subtype. For 
example, round masses are associated with triple negative cancer and irregular masses are 
associated with Luminal cancer186,187; we could not distinguish the two in our data. In addition, 
we observed that after adjustment for age and race, there was no longer an association observed 
between molecular characteristics and mammographic features; although the precision of the 
estimate decreased, the direction of associations remained similar, suggesting that we were 
underpowered to detect these associations. Strengths of this study include an assessment of 
imaging features by race, which is not commonly reported. In addition, associations between 
imaging features and PAM50-derived variables have not been reported previously.  
In summary, considering imaging features, mode of detection, and breast cancer subtype 
together provides a more complete picture of how specific groups of cancers can escape 
detection through mammography. As it appears that the majority of Luminal cancers are detected 
in the presence of calcifications, this work also raises interesting biological questions, such as 
whether aggressive tumors possess a detectable calcification state, or whether they pass through 
this state too quickly to be detected in this state given current screening intervals.  More studies 
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are needed to assess how age and race are related to mammographic feature presentation. In 
addition, future work linking genomics to image features will continue to develop our 
understanding of the limits of mammography and to identify clinical testing or screening 
technologies that could lead to improved screening and diagnosis.  
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Figure 5.1 Flowchart of eligibility criteria. 
 
All linked (CBCS-
CMR)
(N=2614)
Cases 
(N=1743)
Invasive Cases 
(N=1512)
Eligible for analysis 
(N=1497)
Included in 
study 
(N=412)
Excluded: Missing 
imaging feature data
(N=1085)
Excluded: Incorrect match based 
on diagnosis date (N=15)
Excluded: 
DCIS 
(N=231)
Excluded: 
Controls 
(N=871)
Table 5.1 Prevalence and prevalence differences (PD) of mammographic features by demographic characteristics among CBCS-CMR 
linked invasive cases (N=412). 
 Total Any mass Any calcification Mass only 
Age N 
(%) 
N (%) PDa (95% 
C.I.) 
p N (%) PDa (95% 
C.I.) 
p N (%) PDa (95% 
C.I.) 
p 
 ≥ 50 222 98 (44)   56 (25)   77 (35)   
< 50 190 103 
(54) 
8.49  
(-1.05, 18.04) 
0.08 28 (15) -10.88  
(-18.57, -3.20) 
0.006 95 (50) 13.89 
(4.52, 
23.26) 
0.004 
Race           
White 201 81 (40)   51 (25)   64 (32)   
African-
American 
208 120 
(58) 
18.27  
(8.94, 27.60) 
<0.001 33 (16) -9.18  
(-163.98, 
1.38) 
0.02 108 (52) 20.43 
(11.29, 
29.56) 
<0.001 
BI-RADS 
mammographic 
breast densityb 
         
Non-dense 191 99 (52)   34 (18)   87 (46)   
Dense 196 93 (47) -5.84  
(-15.65, 3.97) 
0.2 42 (21) 3.30  
(-4.65, 11.26) 
0.4 79 (40) -6.75 
 (-16.47, 
2.97) 
0.2 
Missing 25 9   8   6   
Stage           
I/II 347 172 
(50) 
  69 (20)   149 (43)   
III/ IV 52 26 (50) -3.16  
(-17.02, 
10.71) 
0.7 11 (21) 1.26  
(-10.65, 
13.17) 
0.8 21 (40) -0.81  
(-0.15, 
0.12) 
0.9 
Missing 13 3   4   2   
Tumor size           
≤ 2 cm 217 97 (45)   50 (23)   84 (39)   
8
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> 2 cm 180 100 
(56) 
10.69 (1.04, 
20.33) 
0.03 30 (17) -6.43 (-0.14, 
1.43) 
0.1 85 (47) 8.61 
 (-0.90, 
18.12) 
0.08 
Missing 15 4   4   3   
Mode of 
detection 
          
Screen 125 58 (46)   31 (25)   50 (40)   
Interval 132 44 (33) -12.45  
(-24.11, 0.78) 
0.04 25 (19) -5.13  
(-15.35, 5.10) 
0.3 37 (28) -11.45  
(-2.69, 
0.21) 
0.05 
Missing 155 99   28   85   
a All prevalence differences adjusted for CBCS Phase. 
bNon-dense= BI-RADS categories 1&2; Dense= BI-RADS categories 3&4. 
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Table 5.2 Prevalence and prevalence difference (PD) of mammographic features by molecular/ genomic characteristics among CBCS-
CMR linked invasive cases (N=412). 
 Total Any mass Any calcification Mass only 
ER N (%) N (%) PDa (95% C.I.) p N (%) PDa (95% C.I.) p N (%) PDa (95% C.I.) p 
Positive 221 100 (45)   45 (20)   84 (38)   
Negative 170  91 (54) 5.28 (-4.69, 
15.25) 
0.3 37 (22) 1.41 (-6.79, 
9.60) 
0.7 78 (46) 4.69 (-5.13, 
14.51) 
0.3 
Missing 21 10   2   10   
PR           
Positive 199 87 (44)   39 (20)   74 (37)   
Negative 192 106 (55) 9.97 (0.19, 
19.75) 
0.05 42 (22) 2.28 (5.76, 
10.31) 
0.6 90 (47) 7.94 (-1.70, 
17.58) 
0.1 
Missing 21 8   3   8   
HER2           
Positive 46 28 (61)   12 (26)   22 (48)   
Negative 308 147 (48) -13.77 (-28.91, 
1.37) 
0.1 56 (18) -7.87 (-21.29, 
5.56) 
0.3 128 (42) -6.05 (-21.49, 
9.38) 
0.4 
Missing 58 26   11   22   
IHC subtype           
Luminal A 196 86 (44)   37 (19)   74 (38)   
Luminal B 22 13 (59) 17.43 (-4.22, 
39.07) 
0.1 4 (18) -0.35 (-16.87, 
17.57) 
1 11 (50) 14.01 (-8.66, 
36.69) 
0.2 
Triple 
negative 
111 60 (54) 3.27 (-0.54, 
7.09) 
0.1 19 (17) -0.56 (-3.54, 
2.43) 
0.7 53 (48) 3.11 (-0.68, 
6.91) 
0.1 
HER2+ 24 15 (63) 8.72 (-1.84, 
19.28) 
0.1 8 (33) 7.17 (-2.58, 
16.91) 
0.1 11 (46) 3.12 (-7.44, 
13.68) 
0.6 
Missing 59 27   16   14   
PAM50           
Luminal A 85 36 (42)   15 (18)   28 (33)   
Luminal B 17 7 (41) -2.40 (-28.85, 
24.05) 
0.9 7 (41) 22.94 (-2.36, 
48.24) 
0.1 4 (23) -9.23 (-12.31, 
30.77) 
0.4 
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Basal-like 49 29 (59) 16.50 (-0.74, 
33.73) 
0.06 4 (8) -9.60 (-20.70, 
1.50) 
0.1 26 (53) 19.88 (2.88, 
36.87) 
0.02 
HER2-
enriched 
18 13 (72) 31.41 (7.31, 
55.51) 
0.01 2 (11) -6.66 (-23.27, 
9.95) 
0.4 12 (66) 32.67 (7.60, 
57.74) 
0.01 
Missing 235 113   53   100   
ROR-PT           
Low 43 16 (37)   8 (19)   12 (28)   
Medium 101 54 (53) 18.67 (-3.48, 
40.83) 
0.1 18 (18) -1.09 (-15.02, 
12.84) 
0.9 44 (44) 17.51 (0.46, 
34.56) 
0.04 
High 30 16 (53) 18.67 (-3.48, 
40.83) 
0.1 3 (10) -7.87 (-23.77, 
8.03) 
0.3 15 (50) 24.27 (2.68, 
45.85) 
0.03 
Missing 235 113   53   100   
a All prevalence differences adjusted for CBCS Phase. 
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Table 5.3 Prevalence and adjusted prevalence difference (PD) of mammographic features by molecular/ genomic characteristics 
among CBCS-CMR linked invasive cases (N=412). 
 Total Any mass Any calcification Mass only 
ER N (%) N (%) PDa (95% C.I.) p N (%) PDa (95% C.I.) p N (%) PDa (95% C.I.) p 
Positive 221 100 (45)   45 (20)   84 (38)   
Negative 170  91 (54) 0.15 (-9.70, 
10.00) 
1.0 37 (22) 3.03 (-4.66, 
10.72) 
0.4 78 (46) 0.73 (-8.40, 
9.85) 
0.9 
Missing 21 10   2   10   
PR           
Positive 199 87 (44)   39 (20)   74 (37)   
Negative 192 106 (55) 6.43 (-3.38, 
16.24) 
0.2 42 (22) 2.75 (-5.04, 
10.55) 
0.5 90 (47) 5.29 (-3.93, 
14.50) 
0.3 
Missing 21 8   3   8   
HER2           
Positive 46 28 (61)   12 (26)   22 (48)   
Negative 308 147 (48) 9.51 (-5.27, 
24.28) 
0.2 56 (18) -8.57 (-21.60, 
4.46) 
0.2 128 (42) 0.39 (-15.20, 
15.98) 
0.9 
Missing 58 26   11   22   
IHC subtype           
Luminal A 196 86 (44)   37 (19)   74 (38)   
Luminal B 22 13 (59) 12.88 (-8.34, 
34.09) 
0.2 4 (18) -3.86 (-22.82, 
15.10) 
0.7 11 (50) 6.71 (-16.72, 
30.14) 
0.6 
Triple 
negative 
111 60 (54) 1.93 (-1.81, 
5.67) 
0.3 19 (17) -1.15 (-4.23, 
1.93) 
0.5 53 (48) 1.78 (-1.80, 
5.36) 
0.3 
HER2+ 24 15 (63) 11.81 (-1.10, 
24.63) 
0.5 8 (33) 7.96 (-1.91, 
17.84) 
0.1 11 (46) 2.00 (-12.64, 
8.63) 
0.7 
Missing 59 27   16   14   
PAM50           
Luminal A 85 36 (42)   15 (18)   28 (33)   
Luminal B 17 7 (41) -1.90 (-28.39, 
24.59) 
0.9 7 (41) 18.90 (-8.28, 
46.08) 
0.2 4 (23) -11.64 (-37.07, 
13.79) 
0.4 
9
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Basal-like 49 29 (59) 13.97 (-4.33, 
32.28) 
0.1 4 (8) -0.49 (-16.51, 
15.52) 
1 26 (53) 14.53 (-2.87, 
31.94) 
0.1 
HER2-
enriched 
18 13 (72) 27.09 (1.10, 
53.09) 
0.04 2 (11) -7.89 (-29.89, 
14.11) 
0.5 12 (66) 22.08 (-4.78, 
48.93) 
0.1 
Missing 235 113   53   100   
ROR-PT           
Low 43 16 (37)   8 (19)   12 (28)   
Medium 101 54 (53) 14.10 (-3.26, 
31.47) 
0.1 18 (18) -0.66 (-14.28, 
12.97) 
0.9 44 (44) 11.50 (-4.12, 
27.11) 
0.1 
High 30 16 (53) 11.51 (-14.64, 
37.67) 
0.4 3 (10) 3.93 (-20.98, 
28.84) 
0.8 15 (50) 17.50 (-7.70, 
42.69) 
0.2 
Missing 235 113   53   100   
a All prevalence differences adjusted for age, race, and CBCS Phase. 
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CHAPTER 6: DISCUSSION 
 
6.1 Summary of Findings 
It has been argued that mammography preferentially detects indolent cancers. The 
purpose of this dissertation research was to better characterize cancers missed by mammography 
as a means of assessing whether this statement is true. To do this, in the first aim, screen vs. 
interval-detected invasive breast cancer cases were compared. We found that aggressive cancer 
characteristics such as large tumor size, high stage, and triple negative subtype were more likely 
to occur ass interval cancers, suggesting that mammography is in fact missing some aggressive 
cancers. In the second aim we then evaluated one explanation for why aggressive cancers may be 
missed, namely that they present with different imaging features. We found that ER-, PR-, triple 
negative, basal-like cancers more commonly presented with masses and seldom presented as 
calcifications. Results from both aims were strengthened using genomic methods, with high risk 
of recurrence (ROR-PT) score being associated with both interval cancers and cancers that 
present as a mass. 
 Joining these results together can provide a more complete picture of how specific 
groups of cancers can escape detection through screening. The underlying biology of the tumor 
may affect mammographic detection rates in two ways. First, aggressive cancers may evade 
detection by possessing biologic characteristics that lead to rapid progression, resulting in 
detection between screenings. Secondly, they can present with features that are difficult to detect 
mammographically. Overall, these results aligned with our study hypotheses, that cancers 
detected outside of screening would possess negative prognostic characteristics compared to 
94 
 
those detected by screening and that subtype-specific patterns of mammographic features would 
exist. 
6.2 Significance 
Understanding characteristics of cancers that evade mammographic detection helps to 
pinpoint areas of improvement for breast cancer screening. Although mammography is currently 
the most common breast cancer screening method, it is surrounded by significant controversy. 
Missed cancers, or false negatives of mammography, which occur in approximately 1 out of 
1000 women when using digital mammography232, is one major source of debate. Missed 
cancers, which are often attributed to masking caused dense breasts, represent a challenge not 
only on the individual level but also with respect to public perceptions of mammography, as 
evidenced by the rapid passing of density notification laws in the majority of the United States. 
There is strong evidence that the sensitivity of mammography is reduced among women with 
dense breasts71,167; however as found in this study and others72-74, associations between 
aggressive tumor characteristics and interval vs. screen detection were stronger among women 
with fatty breasts, suggesting that cancer biology also plays a role in missed cancers. This is 
important to highlight as it means that intrinsic technological limitations of mammography in 
dense breasts may not be the sole reason for missed cancers. Another aspect of mammography 
that causes debate is overdetection; though mammography increases the proportion of early stage 
cancer detected, lower impact of mammography in reducing incidence of advanced stage cancer 
has been observed, suggesting overdiagnosis of indolent cancers15-17.  
Newer breast cancer screening methods such as tomosynthesis address some of these 
limitations of mammography. First, tomosynthesis is hypothesized to be more sensitive among 
women with dense breasts, and to be more sensitive cancers, reducing false negative breast 
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cancer screening rates233,234. In addition, tomosynthesis may also detect smaller masses228,229. Put 
into context of the findings of the second aim of this dissertation, this suggests that 
tomosynthesis may be better at detecting aggressive cancers than mammography and in the 
future, could be an alternative or companion screening test to conventional two-dimensional 
mammography.  
In addition to improving imaging methods, technology may drive improvements in 
genomic testing to reduce the harms of screening.  Even if mammography leads to overdetection 
of indolent cancers, our results suggest, that the risk of recurrence score could be used a 
companion diagnostic at the time of diagnosis to determine whether a breast cancer is indolent or 
has a high risk of recurrence. If confirmed, these findings could help guide not only treatment 
decisions, but also breast-conservation options. 
6.3 Limitations 
In Aim 1, some limitations arose due to utilization of data linkage methods to combine 
molecular and mammography data. We expect that we had incomplete registry information on 
mammographic information for some women. The CMR does not cover all breast imaging 
facilities in North Carolina, so we may have missed mammography information for linked 
women who visited a facility that is not part of CMR either before or after utilizing a CMR 
facility. This type of missing information would lead to misclassification of mode of detection. 
Because CMR does not include all breast imaging facilities in North Carolina, only ~30% of 
women enrolled in CBCS were linked to CMR. Furthermore, CBCS oversampled younger and 
African American women, and therefore the proportion of screen and interval detected cases may 
vary as a function of the demographic and selection characteristics of CBCS48.  Therefore, our 
study was not designed to estimate the proportion of screen and interval-detected cases in the 
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general population. We were also unable to retrospectively review mammographic images to 
identify interval cases that arose from false negatives. Studies have shown that the false negative 
rate among interval cancers is around 20%72,157,158.  
Data on clinical relevance of our imaging features was limited for our study. That is, 
calcifications that were noted on a mammogram may not have been central to detection for a 
given cases. We also lacked detailed information of mammographic features such as mass shape 
(irregular/ lobulated/ oval/ round), mass margins (noncircumscribed/ circumscribed), and 
calcification type (round/ amorphous/ fine linear), some of which have been shown to be 
associated with breast cancer subtype187,230,231. Heterogeneity within imaging feature groups may 
have attenuated some of our associations with subtype. For example, round masses are 
associated with triple negative cancer and irregular masses are associated with Luminal 
cancer186,187; we could not distinguish the two in our data. Despite these limitations, the research 
presented here provides valuable information on mammography and is one of the first to 
incorporate genomic data, which is becoming increasingly utilized in the clinical setting. 
6.4 Future Directions 
There are several areas of uncertainty that should be prioritized in future research on 
breast cancer screening. First, there are remaining uncertainties about efficacy of mammography 
by race. In both aims, we observed racial differences in the presentation of cancers, which have 
not been well-studied. In Aim 1, associations between aggressive cancer characteristics and 
interval-detected cancers were stronger in Black women compared to White women. In Aim 2, 
Black women were more likely to present with masses compared to White women, and were less 
likely to present with calcifications. Mode of detection and mammographic features may reflect 
underlying subtype-specific associations by race since triple negative cancers, which are fast 
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growing and are likely to present with a mass, are more prevalent among African-American 
women. Future directions of this research should leverage the resources of surveillance consortia 
to study the biological characteristics of interval cancers that occur among Black women.  
Alternatively, clinical trials designed to assess the efficacy of tomosynthesis vs. digital 
mammography should evaluate race-specific performance in both arms. 
Another important area for future research is the use of health insurance data in studies of 
mammography and breast cancer screening.  United States-based studies often have had less 
complete mammographic data relative to European studies based on single-payer health care 
data. Use of insurance claims data could provide a more complete history of mammography use 
for women, allowing for better classification of mode of detection. In addition, such studies 
could help to better characterizing screening behavior. Screening behavior is commonly tracked 
by evaluating both initiation and adherence. Factors that affect screening initiation and adherence 
may lead to selection bias in studies that evaluate tumor biology of screen-detected vs. non-
screen-detected cancers. Understanding these factors is important when interpreting the results of 
mammography.  
Finally, our data suggest that the biologic features of cancer subtypes are often present 
from the earliest stages, affecting not just clinical outcomes but patterns of detection. However, 
the specific biological mechanism underlying the association between subtype and imaging 
features are still poorly understood. Specifically, the natural history of calcifications are not well-
understood, and are crucial in understanding why basal-like cancers are often not detected with 
calcifications. It is unclear whether basal-like cancers have an early, calcification stage that could 
be detectable by more frequent screenings, or whether some cancers are only detectable as 
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masses. One approach to addressing this question would be to identify genes or histologic 
features that are associated with calcifications.  
6.5 Conclusions 
The linked Carolina Breast Cancer Study and the Carolina Mammography Registry data 
set provided a unique resource, with both data sets contributing high quality data.  Screening and 
mammographic data from CMR was complemented with epidemiologic, clinical, and molecular 
data from CBCS. Using a racially diverse data set with well-characterized tumor biology, this 
dissertation elucidated the relationship between breast cancer subtype, imaging features, and 
mode of detection in a heterogeneous population of North Carolina women. Understanding the 
limitations and failures of mammography highlight priority areas of screening improvement and 
helps prioritize research questions in the context of evolving radiologic practices. 
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APPENDIX A: MAMMOGRAPHY RECOMMENDATIONS (CBCS 1-3) 
 
CBCS Phase 1 (1993-1996) 
 1990 1991 1992 1993 
Organization     
ACS 35-39: Baseline Mammogram 
 
40-49: Every 1-2 yrs 
 
50+: yearly 
40-49: Every 1-2 yrs 
 
50+: yearly 
ACOG 35-39: Baseline Mammogram 
 
40-49: Every 1-2 yrs 
 
50+: yearly 
USPSTF  
 
CBCS Phase 2 (1996-2001) 
 1993  1994 1995 1996 1997 1998 
Organization        
ACS  40-49: Every 1-2 yrs 
 
50+: yearly 
40+ yearly 
ACOG  40-49: 1-2 yrs 
 
50+: yearly 
USPSTF   40+: Every 1-2 years 
 
CBCS Phase 3 (2008-2013) 
 2005 2006 2007 2008 2009 2010 
Organization       
ACS 40+: yearly 
ACOG 40-49: 1-2 years 
 
50+: annual 
USPSTF 40+: Every 1-2 years Before 50: up to the 
woman 
 
50-74: biennial 
 
75+: insufficient 
evidence 
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APPENDIX B: STUDIES OF INTEREST 
 
Table B1. Percent of interval cancers in different study populations 
Author Study Population Screening Interval Percent of cancers 
that were interval-
detected 
Ikeda, 199250 Malmo Mammographic 
Screening Trial 
 
18-24 months 17% 
Klemi, 199749 Population based 
screening program in 
Finland 
1-3 years, depending on 
age 
Age 40-49: 1 year 
interval: 27% 
Age 40-49: 3 year 
interval: 39% 
 
Age 50-74” 2 year 
interval: 18% 
Porter, 199948 Women from HMO 
(Group Health 
Cooperative of Puget 
Sound) also enrolled in 
Breast Cancer Screening 
Program 
2 years 28%  
 
Hofvind, 
200954 
Screening program in 
Norway 
2 years 26% 
 
CMR 1-2 years 38% 
Kirsh, 201169 Ontario Breast Screening 
Program  
 
Biennial screening, but 
women who were 
determined to be high risk 
were screened annually 
13.8%, of which 
77% were true 
interval cancers 
 
Nederend, 
201452 
Breast cancer screening 
program in the 
Netherlands 
2 years 
 
23.9% 
Bento, 201453 Breast cancer screening 
program in Portugal 
2 years 20.2% 
Henderson, 
201551 
Breast Cancer 
Surveillance Consortium 
1 year 14.7% 
 
 
Table B2. Studies of interest related to Aim 1: Subtype & mode of detection 
Author, 
year 
Population Outcome Interval used Predictor Key Results 
Kirsh, 
201169 
Ontario Breast 
Screening 
Program 
(women>50) 
 
January 1, 
1994- 
December 31, 
2002 
Screen-detected (referent, 
n=450) vs. 
Interval 
(n=375) 
 
IC= diagnosed before the 
next recommended screening 
visit after a negative 
screening mammo 
 
SDC= Diagnosed after a 
positive screening mammo 
Most women 
participating in 
OBSP are screened 
every two years, 
women considered 
at high-risk for BC 
are examined 
annually 
 
Lymph node + 
OR=1.41, 95%CI 
(1.01,1.96) 
Tumor size (<10 
mm referent) 
10-15 mm: OR=2.04, 95% 
CI (1.34, 3.11) 
16-20 mm: OR=3.70, 95% 
CI (2.28, 5.95) 
>20 mm: OR=4.83, 95% CI 
(3.09, 5.75) 
 
Stage at 
diagnosis (I is 
referent) 
II: OR=2.16, 95% CI (1.39, 
3.36) 
III or IV: OR=4.46, 95% 
CI (1.12, 17.70) 
 
ER - 
OR=1.68, 95% CI (1.09, 
2.59) 
PR - 
OR=2.07, 95% CI (1.43, 
2.98) 
Domingo, 
201468 
Population 
based 
screening 
program in 
Spain (women 
50-69) 
 
2000-2009 
Screen-detected (referent, 
n=1297) vs. Interval (n=455) 
 
IC: primary BC arising after 
a negative screening episode, 
with or without further 
assessment, and before the 
next invitation to screening, 
or within 24 months for 
women who reached the 
upper age limit 
Women invited to 
participate by 
written letter every 
2 years 
 
 
 
 
 
 
Lymph node + 
SDC: 29.8% 
IC: 49.6% 
ER- 
SDC: 17.5% 
IC: 36.8% 
Luminal A+B 
SDC: 83.4% 
IC: 66.4% 
Triple negative 
SDC: 9.9% 
IC: 19.9% 
1
0
1
 
Rayson, 
201191 
Nova Scotia 
Breast 
Screening 
Program 
Screen-detected (referent, n= 
481) 
 
Interval (n=241) 
 
IC= interval cancers were 
true interval cancers- 
negative screening mammos 
were re-reviewed by 3 
independent radiologists 
1 year and 2 year Triple negative 
Women 40-49: OR= 1.36, 
95% CI (0.19, 9.67) 
 
Women 50-69 with 1 year 
interval: OR=1.72, 95% CI 
(0.29, 10.2) 
 
Women 50-69 with 2 year 
interval: 
OR=2.28, 95% CI (1.05, 
4.94) 
Caldarella, 
201377 
Population 
based 
screening 
program in 
Italy 
Screen-detected 
(referent,N=211) 
Interval (N=66) 
2 year 
Triple negative 
(LumA is 
referent) 
OR= 3.52 (1.12, 11.13) 
HER2 (LumA is 
referent) 
OR= 1.57 (0.46, 5.29) 
Gilliland, 
200070 
New Mexico 
Mammography 
Project 
Screen-detected (referent, 
n=63) 
 
Interval (n=64) 
1 year p53 expression 
OR=2.96, 95% CI (1.07, 
8.20) 
Collett, 
2005138 
Norwegian 
Breast Cancer 
Screening 
Program 
Screen (referent, n=95) 
 
Interval (n=95) 
2 year 
 
 
 
 
 
 
 
 
p53 high 
expression 
OR=4.0, 95% CI (1.6, 12.0) 
*Interval cancer was cancer detected 24 months after negative screening mammogram 
 
 
1
0
2
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Schroen, 
1996102 
Netherlands, 
hospital based, 
retrospective 
analysis of 
women 
referred for 
breast cancer 
from 1975-
1990 
SDC (N=173) 
Interval (N=76) 
 
Other [patients who were 
never invited to screening 
program, patients who chose 
not to attend, and patients 
who developed breast cancer 
>2 years after attending the 
screening program] (N=688) 
2 year 
Tumor size >5 
cm 
Positive lymph 
node status 
SDC: 9% 
Interval: 10% 
Other: 12% 
SDC: 19% 
Interval: 40% 
Other: 32% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sg 
1
0
3
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Table B3. Studies of interest related to Aim 2: Subtype & imaging features 
Author, 
year 
Population Subtype Key Results 
An, 
2015225 
Women <30 who 
underwent surgery to 
treat breast cancer in 
South Korea 
Triple negative (n=6) 
 
ER+ (n=40) 
 
HER2 enriched (n=4) 
80% of triple negative breast and 65% of 
ER+ cancers presented with a mass and no 
calcifications 
 
 
 
Boisserie-
Lacroix, 
2013187 
Database from French 
hospital 
Triple negative (n=92) 
 
ER+/PR+/HER2+ 
(n=95) 
8.7% of TN present as mass with 
calcification vs. 5.3 of Luminal B 
Ko, 
2010153 
Database from Korean 
hospital 
Triple negative (N=87) 
 
ER+/PR-/HER2- (n=93) 
 
ER-/PR-/HER2+ (n=65) 
TN cancers usually presented with a mass 
 
HER2 more likely to present with 
calcifications 
 
Wang, 
2010226 
Chinese women who 
underwent breast surgical 
treatment 
Basal like (n=40) 
Non-basal like (n=227) 
Basal-like more likely to present with mass 
and less likely to present with architectural 
distortion 
Yang, 
2008154 
Premenopausal women 
<45 
TN (n=38) 
HER2+ (n=67) 
ER+ (n=93) 
TN more likely to be associated with a mass 
 
HER2 more likely to present with 
calcifications 
Killelea, 
2013141 
Database from Yale 
hospital 
LumA (n=703) 
LumB (n=78) 
HER2 (n=59) 
TN (n=145) 
TN more likely to be associated with a mass 
 
HER2 more likely to present with 
calcifications 
 
Luminal cancers more likely to present with 
architectural distortion 
1
0
4
 
sg 
sg 
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